<teiCorpus>
    <teiCorpus>
        <teiHeader type="application">
            <fileDesc>
                <titleStmt>
                    <title>Patent application information</title>
                </titleStmt>
                <publicationStmt>
                    <authority>European Patent Office</authority>
                </publicationStmt>
                <sourceDesc>
                    <biblStruct type="patent" subtype="docdb" status="application">
                        <monogr>
                            <authority>
                                <orgName type="national">JP</orgName>
                            </authority>
                            <idno type="docNumber">2000593625</idno>
                            <imprint>
                                <classCode scheme="kindCode">A</classCode>
                                <date>20000119</date>
                            </imprint>
                        </monogr>
                        <idno type="doc-id">37185318</idno>
                        <idno type="is-representative">NO</idno>
                    </biblStruct>
                    <biblStruct type="patent" subtype="epodoc" status="application">
                        <monogr>
                            <idno type="docNumber">JP20000593625</idno>
                        </monogr>
                    </biblStruct>
                    <biblStruct type="patent" subtype="original" status="application">
                        <monogr>
                            <idno type="docNumber">2000593625</idno>
                        </monogr>
                    </biblStruct>
                </sourceDesc>
            </fileDesc>
        </teiHeader>
        <TEI>
            <teiHeader type="publication">
                <fileDesc>
                    <titleStmt>
                        <title>Patent publication information</title>
                    </titleStmt>
                    <publicationStmt>
                        <authority>European Patent Office</authority>
                    </publicationStmt>
                    <notesStmt>
                        <note type="exchange-document">
                            <idno type="is-representative">YES</idno>
                            <idno type="date-of-last-exchange">20130328</idno>
                            <idno type="date-added-docdb">20110625</idno>
                            <idno type="originating-office">EP</idno>
                        </note>
                    </notesStmt>
                    <sourceDesc>
                        <biblStruct type="patent" subtype="docdb" status="publication">
                            <monogr>
                                <authority>
                                    <orgName type="national">JP</orgName>
                                </authority>
                                <idno type="docNumber">2002534532</idno>
                                <imprint>
                                    <classCode scheme="kindCode">A</classCode>
                                    <date>20021015</date>
                                </imprint>
                            </monogr>
                        </biblStruct>
                        <biblStruct type="patent" subtype="epodoc" status="publication">
                            <monogr>
                                <idno type="docNumber">JP2002534532</idno>
                            </monogr>
                        </biblStruct>
                        <listBibl type="priority-claims">
                            <biblStruct type="patent" subtype="docdb" status="application" rend="1">
                                <monogr>
                                    <authority>
                                        <orgName type="national">US</orgName>
                                    </authority>
                                    <idno type="docNumber">23400899</idno>
                                    <imprint>
                                        <classCode scheme="kindCode">A</classCode>
                                        <date>19990119</date>
                                    </imprint>
                                </monogr>
                                <idno type="priority-active-indicator">Y</idno>
                            </biblStruct>
                            <biblStruct type="patent" subtype="epodoc" status="application" rend="1">
                                <monogr>
                                    <idno type="docNumber">US19990234008</idno>
                                </monogr>
                            </biblStruct>
                            <biblStruct type="patent" subtype="docdb" status="application" rend="2">
                                <monogr>
                                    <authority>
                                        <orgName type="national">US</orgName>
                                    </authority>
                                    <idno type="docNumber">0001314</idno>
                                    <imprint>
                                        <classCode scheme="kindCode">W</classCode>
                                        <date>20000119</date>
                                    </imprint>
                                </monogr>
                                <idno type="priority-linkage-type">W</idno>
                                <idno type="priority-active-indicator">N</idno>
                            </biblStruct>
                            <biblStruct type="patent" subtype="epodoc" status="application" rend="2">
                                <monogr>
                                    <idno type="docNumber">WO2000US01314</idno>
                                </monogr>
                            </biblStruct>
                            <biblStruct type="patent" subtype="original" status="application" rend="1">
                                <monogr>
                                    <idno type="docNumber">1999 234008</idno>
                                </monogr>
                            </biblStruct>
                            <biblStruct type="patent" subtype="original" status="application" rend="2">
                                <monogr>
                                    <idno type="docNumber">2000/01314</idno>
                                </monogr>
                            </biblStruct>
                        </listBibl>
                        <list type="additional-bibliographic-information">
                            <item type="dates-of-public-availability">
                                <list>
                                    <item type="unexamined-printed-without-grant">
                                        <biblStruct>
                                            <monogr>
                                                <imprint>
                                                    <date>20021015</date>
                                                </imprint>
                                            </monogr>
                                        </biblStruct>
                                    </item>
                                </list>
                            </item>
                            <item type="references-cited">
                                <list type="citations">
                                    <item type="citation" rend="1">
                                        <idno type="srep-phase">SEA</idno>
                                        <biblStruct type="patent">
                                            <monogr rend="1">
                                                <authority>
                                                    <orgName type="national">US</orgName>
                                                </authority>
                                                <idno type="docNumber">5583239</idno>
                                                <imprint>
                                                    <classCode scheme="kindCode">A</classCode>
                                                    <date>19961210</date>
                                                </imprint>
                                            </monogr>
                                            <idno type="dnum">US5583239A</idno>
                                            <idno type="dnum-type">publication number</idno>
                                        </biblStruct>
                                    </item>
                                    <item type="citation" rend="2">
                                        <idno type="srep-phase">SEA</idno>
                                        <biblStruct type="patent">
                                            <monogr rend="2">
                                                <authority>
                                                    <orgName type="national">US</orgName>
                                                </authority>
                                                <idno type="docNumber">4029775</idno>
                                                <imprint>
                                                    <classCode scheme="kindCode">A</classCode>
                                                    <date>19770614</date>
                                                </imprint>
                                            </monogr>
                                            <idno type="dnum">US4029775A</idno>
                                            <idno type="dnum-type">publication number</idno>
                                        </biblStruct>
                                    </item>
                                    <item type="citation" rend="1">
                                        <idno type="srep-phase">EXA</idno>
                                        <biblStruct type="patent">
                                            <monogr rend="1">
                                                <authority>
                                                    <orgName type="national">JP</orgName>
                                                </authority>
                                                <idno type="docNumber">2010059194</idno>
                                                <imprint>
                                                    <classCode scheme="kindCode">A</classCode>
                                                    <date>20100318</date>
                                                </imprint>
                                            </monogr>
                                            <idno type="dnum">JP2010059194A</idno>
                                            <idno type="dnum-type">publication number</idno>
                                        </biblStruct>
                                    </item>
                                </list>
                            </item>
                        </list>
                    </sourceDesc>
                </fileDesc>
                <profileDesc>
                    <textClass type="classification-ipc">
                        <classCode scheme="ipc">
                            <term type="main-classification">7C 07J 9/00 A</term>
                        </classCode>
                        <classCode scheme="ipc">
                            <term type="further-classification">7A 61K 31/575 B</term>
                        </classCode>
                        <classCode scheme="ipc">
                            <term type="further-classification">7A 61P 31/04 B</term>
                        </classCode>
                    </textClass>
                    <textClass type="classifications-ipcr">
                        <classCode scheme="ipcr" rend="1">
                            <term type="text">A61K 31/575 20060101AFI20051220RMJP</term>
                        </classCode>
                        <classCode scheme="ipcr" rend="2">
                            <term type="text">A61K 31/56 20060101A I20051110RMEP</term>
                        </classCode>
                        <classCode scheme="ipcr" rend="3">
                            <term type="text">A61P 31/04 20060101ALI20051220RMJP</term>
                        </classCode>
                        <classCode scheme="ipcr" rend="4">
                            <term type="text">C07J 9/00 20060101ALI20051220RMJP</term>
                        </classCode>
                        <classCode scheme="ipcr" rend="5">
                            <term type="text">C07J 41/00 20060101A I20051110RMEP</term>
                        </classCode>
                    </textClass>
                </profileDesc>
            </teiHeader>
            <text>
                <front></front>
            </text>
        </TEI>
        <TEI>
            <teiHeader type="publication">
                <fileDesc>
                    <titleStmt>
                        <title>Patent publication information</title>
                    </titleStmt>
                    <publicationStmt>
                        <authority>European Patent Office</authority>
                    </publicationStmt>
                    <notesStmt>
                        <note type="exchange-document">
                            <idno type="is-representative">NO</idno>
                            <idno type="date-of-last-exchange">20130328</idno>
                            <idno type="date-added-docdb">20130312</idno>
                            <idno type="originating-office">EP</idno>
                        </note>
                    </notesStmt>
                    <sourceDesc>
                        <biblStruct type="patent" subtype="docdb" status="publication">
                            <monogr>
                                <authority>
                                    <orgName type="national">JP</orgName>
                                </authority>
                                <idno type="docNumber">5139609</idno>
                                <imprint>
                                    <classCode scheme="kindCode">B2</classCode>
                                    <date>20130206</date>
                                </imprint>
                            </monogr>
                        </biblStruct>
                        <biblStruct type="patent" subtype="epodoc" status="publication">
                            <monogr>
                                <idno type="docNumber">JP5139609B2</idno>
                            </monogr>
                        </biblStruct>
                        <listBibl type="priority-claims">
                            <biblStruct type="patent" subtype="docdb" status="application" rend="1">
                                <monogr>
                                    <authority>
                                        <orgName type="national">US</orgName>
                                    </authority>
                                    <idno type="docNumber">23400899</idno>
                                    <imprint>
                                        <classCode scheme="kindCode">A</classCode>
                                        <date>19990119</date>
                                    </imprint>
                                </monogr>
                                <idno type="priority-active-indicator">Y</idno>
                            </biblStruct>
                            <biblStruct type="patent" subtype="epodoc" status="application" rend="1">
                                <monogr>
                                    <idno type="docNumber">US19990234008</idno>
                                </monogr>
                            </biblStruct>
                            <biblStruct type="patent" subtype="docdb" status="application" rend="2">
                                <monogr>
                                    <authority>
                                        <orgName type="national">US</orgName>
                                    </authority>
                                    <idno type="docNumber">0001314</idno>
                                    <imprint>
                                        <classCode scheme="kindCode">W</classCode>
                                        <date>20000119</date>
                                    </imprint>
                                </monogr>
                                <idno type="priority-linkage-type">W</idno>
                                <idno type="priority-active-indicator">N</idno>
                            </biblStruct>
                            <biblStruct type="patent" subtype="epodoc" status="application" rend="2">
                                <monogr>
                                    <idno type="docNumber">WO2000US01314</idno>
                                </monogr>
                            </biblStruct>
                            <biblStruct type="patent" subtype="original" status="application" rend="1">
                                <monogr>
                                    <idno type="docNumber">1999 234008</idno>
                                </monogr>
                            </biblStruct>
                            <biblStruct type="patent" subtype="original" status="application" rend="2">
                                <monogr>
                                    <idno type="docNumber">2000/001314</idno>
                                </monogr>
                            </biblStruct>
                        </listBibl>
                        <list type="additional-bibliographic-information">
                            <item type="dates-of-public-availability">
                                <list>
                                    <item type="printed-with-grant">
                                        <biblStruct>
                                            <monogr>
                                                <imprint>
                                                    <date>20130206</date>
                                                </imprint>
                                            </monogr>
                                        </biblStruct>
                                    </item>
                                </list>
                            </item>
                        </list>
                    </sourceDesc>
                </fileDesc>
                <profileDesc>
                    <textClass type="classifications-ipcr">
                        <classCode scheme="ipcr" rend="1">
                            <term type="text">A61K 31/575 20060101AFI20051220RMJP</term>
                        </classCode>
                        <classCode scheme="ipcr" rend="2">
                            <term type="text">C07J 9/00 20060101AFI20130117BHJP</term>
                        </classCode>
                        <classCode scheme="ipcr" rend="3">
                            <term type="text">A61K 31/56 20060101A I20051110RMEP</term>
                        </classCode>
                        <classCode scheme="ipcr" rend="4">
                            <term type="text">A61P 31/04 20060101ALI20051220RMJP</term>
                        </classCode>
                        <classCode scheme="ipcr" rend="5">
                            <term type="text">C07J 41/00 20060101A I20051110RMEP</term>
                        </classCode>
                    </textClass>
                    <creation>
                        <listChange>
                            <change xml:id="364fce958c61faa8e1e3bb411cbb6736">
                                <date type="date-produced">2013-02-06</date>
                                <orgName type="supplier">THOMSON</orgName>
                                <idno type="format-subtype">MAT</idno>
                                <idno type="quality-level">01</idno>
                                <language ident="EN"/>
                            </change>
                        </listChange>
                    </creation>
                </profileDesc>
            </teiHeader>
            <text>
                <front></front>
                <group>
                    <text change="364fce958c61faa8e1e3bb411cbb6736">
                        <body>
                            <div xml:lang="en" type="claims">
                                <div n="0001" type="claim" xml:id="_bb67360003">
                                    <p xml:id="_bb67360004">The compound of the following formula I, or
                                        pharmacologically acceptable salt thereof:
                                        <formula n="0001" xml:id="_bb67360005">
                                            <figure xml:id="_bb67360006">
                                                <graphic url="/1"/>
                                            </figure>
                                        </formula>
                                        (In Formula,<lb/>The condensed ring A, B, and C and D are saturated;<lb/>R1, R2,
                                        R4-R6, R8, R10-R11, R14-R16 shows hydrogen;<lb/>R9 and R13 show -CH3;<lb/>R3, R7
                                        and R12 show (C1-C10) aminoalkyl oxy or (C1-C10) guanidino alkyloxy;<lb/>R17
                                        shows -CH(CH3)(CH2)3- amino- (C1-C10) alkyl.
                                    </p>
                                </div>
                                <div n="0002" type="claim" xml:id="_bb67360012">
                                    <p xml:id="_bb67360013">The compound of Claim 1 whose R17 is
                                        -CH(CH3)(CH2)3-NH-(CH2)7CH3, or pharmacologically acceptable salt thereof.
                                    </p>
                                </div>
                                <div n="0003" type="claim" xml:id="_bb67360014">
                                    <p xml:id="_bb67360015">The compound of Claim 1 or 2 whose R3, R7 and R12 are
                                        -O(CH2)2-NH2, -O(CH2)3-NH2 or -O(CH2)3-NH-C(=NH)NH2, or pharmacologically
                                        acceptable salt thereof.
                                    </p>
                                </div>
                                <div n="0004" type="claim" xml:id="_bb67360016">
                                    <p xml:id="_bb67360017">The compound represented by following formula|equation
                                        <formula n="0002" xml:id="_bb67360018">
                                            <figure xml:id="_bb67360019">
                                                <graphic url="/1"/>
                                            </figure>
                                        </formula>
                                        , or pharmacologically acceptable salt thereof.
                                    </p>
                                </div>
                                <div n="0005" type="claim" xml:id="_bb67360020">
                                    <p xml:id="_bb67360021">The compound represented by following formula|equation
                                        <formula n="0003" xml:id="_bb67360022">
                                            <figure xml:id="_bb67360023">
                                                <graphic url="/1"/>
                                            </figure>
                                        </formula>
                                        , or pharmacologically acceptable salt thereof.
                                    </p>
                                </div>
                                <div n="0006" type="claim" xml:id="_bb67360024">
                                    <p xml:id="_bb67360025">The compound of the following formula I, or
                                        pharmacologically acceptable salt thereof:
                                        <formula n="0004" xml:id="_bb67360026">
                                            <figure xml:id="_bb67360027">
                                                <graphic url="/1"/>
                                            </figure>
                                        </formula>
                                        (In Formula,<lb/>The condensed ring A, B, and C and D are saturated;<lb/>R1, R2,
                                        R4-R6, R8, R10-R11, R14-R16 shows hydrogen;<lb/>R9 and R13 show -CH3;<lb/>R3, R7
                                        and R12 are -O-C(O)-(CH2)n-NH2 whose n is 2;<lb/>R17 is -CH(CH3)(CH2)3-OH or
                                        -CH(CH3)(CH2)3-N(CH3)CH2Ph.
                                    </p>
                                </div>
                                <div n="0007" type="claim" xml:id="_bb67360033">
                                    <p xml:id="_bb67360034">Following formula|equation<lb/>(In formula, n is 2)<lb/>The
                                        compound represented by this, or pharmacologically acceptable salt thereof.
                                    </p>
                                </div>
                                <div n="0008" type="claim" xml:id="_bb67360037">
                                    <p xml:id="_bb67360038">The compound represented by following formula|equation
                                        <lb/>
                                        (In formula, R and R' show hydrogen, and n is 2.), or pharmacologically
                                        acceptable salt thereof.
                                    </p>
                                </div>
                            </div>
                            <div xml:lang="en" xmlns:xml="http://www.w3.org/XML/1998/namespace" type="description">
                                <p xml:id="_bb67360041" n="0001">A cross reference of related application<lb/>This
                                    application is a continuation-in-part application of PCT/US 98/No. 04489 for which
                                    it applied as of March 6, 1998.
                                </p>
                                <p xml:id="_bb67360043" n="0002">The background of invention<lb/>This invention relates
                                    to the process and intermediate body for preparing a novel steroid derivative and
                                    these compounds.
                                </p>
                                <p xml:id="_bb67360045" n="0003">The several compound which associates to
                                    outside-film|membrane of Gram-negative bacteria strongly destroying
                                    outside-film|membrane, and making permeability|transmittance increase is known.
                                    <lb/>
                                    A pervious|transmissive increase may make the sensitivity with respect to the other
                                    antibiotics of Gram-negative bacteria increase.<lb/>It is polymyxin antibiotics
                                    which research is following most with this type of compound.<lb/>The example of the
                                    test which investigates the coupling|bonding of the polymyxin B with respect to
                                    structural components with main outside-film|membrane of Gram-negative bacteria
                                    (lipid A),<lb/>D.C. Refer Morrison &amp; Jacobus (D.C. Morrison and D. M. Jacobs),
                                    &quot;joint (Binding of Polymixin B to The Lipid a Portion of Bacterial
                                    Lipopolysaccharides) of the polymyxin B with respect to the lipid which is a part of
                                    bacteria lipopolysaccharide&quot;, a Immunochemistry 1976, 13 volume, and 813-819.
                                    <lb/>Regarding the example of the test including the coupling|bonding of the
                                    polymyxin derivative|guide_body with respect to Gram-negative bacteria,<lb/>M. Refer
                                    ƒoƒAƒ‰ &amp;P. ƒrƒ‹ƒ„ƒlƒ“ (M. Vaara and P. Viljanen), &quot;joint (Binding of
                                    Polymyxin B Nonapeptide to Gram-negative Bacteria) of the polymyxin B nonapeptide
                                    with respect to Gram-negative bacteria&quot;, a Antimicrobial Agents and
                                    Chemotherapy, 1985, 27 volume, and 548-554.
                                </p>
                                <p xml:id="_bb67360052" n="0004">The film|membrane of Gram-negative bacteria is a
                                    semipermeable|semi-transmissive molecule|numerator &quot;sieve&quot; which
                                    restrict|limits access of the antibiotics with respect to the target in a bacteria
                                    cell, and a host defense molecule|numerator.<lb/>Thus, the cation which can interact
                                    with the pervious|transmissive barrier of outside-film|membrane and can
                                    decompose|disassemble it, and the poly cation can make the sensitivity of
                                    antibiotics and the Gram-negative-bacterium venereal-disease original microbe with
                                    respect to a host defense molecule|numerator increase.<lb/>The Hancock &amp; one
                                    (Hancock and Wong) made the name a &quot;permeation|transmission agent&quot;, in
                                    order to authenticate that an extensive peptide can permeate|transmit a
                                    pervious|transmissive barrier and to describe them.<lb/>(The Hancock &amp; one
                                    (Hancock and Wong), Antimicrob. Agents Chemother. 26:48, 1984).
                                </p>
                                <p xml:id="_bb67360056" n="0005">The outline|summary of invention<lb/>This invention is
                                    characterized by the compound of the formula I.
                                    <formula n="0009" xml:id="_bb67360058">
                                        <figure xml:id="_bb67360059">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    In formula,<lb/>It becomes independent, and the condensed ring A, B, and C and D are
                                    saturated, or perfect or partially unsaturated;<lb/>and<lb/>R1-R4, R6, R7, R11, R12,
                                    R15, R16 and R17 respectively.<lb/>Hydrogen, hydroxyl, substituted or unsubstituted
                                    (C1-C10) alkyl,<lb/>(C1-C10) A hydroxyalkyl, (C1-C10) alkyloxy (C1-C10) alkyl,
                                    <lb/>
                                    (C1-C10) alkylamino (C1-C10) alkyl, a substituted or unsubstituted (C1-C10)
                                    aminoalkyl,<lb/>The bonding group, substituted or unsubstituted (C1-C10) aminoalkyl
                                    oxy, the substituted or unsubstituted (C1-C10) aminoalkyl carboxy which were
                                    couple|bonded with substituted or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6
                                    alkenyl, C2-C6 alkynyl, an oxo, and 2nd steroid,<lb/>A substituted or unsubstituted
                                    (C1-C10) aminoalkyl aminocarbonyl,<lb/>The substituted or unsubstituted (C1-C10)
                                    aminoalkyl carboxamide,<lb/>H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10)
                                    azide alkyloxy (C1-C10) cyano alkyloxy,<lb/>It independently selects from P. G.
                                    -HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy and (C1-C10) the group which consists
                                    of a guanidino alkyl carboxy, in Formula, Q5 is a side chain of arbitrary amino
                                    acids (the side chain of glycine, i.e., H, is included), and P. G. is an amino
                                    protecting group.<lb/>and<lb/>R5, R8, R9, R10, R13 and R14 are deleted, when one of
                                    the :condensed ring A, B, and C or the D is respectively independently unsaturated
                                    in order to make perfect the valence of the carbon atom in the site|part.<lb/>or
                                    <lb/>Hydrogen, hydroxyl, substituted or unsubstituted (C1-C10) alkyl,<lb/>(C1-C10) A
                                    hydroxyalkyl, (C1-C10) alkyloxy (C1-C10) alkyl,<lb/>A substituted or unsubstituted
                                    (C1-C10) aminoalkyl, substituted or unsubstituted aryl,<lb/>The bonding group,
                                    substituted or unsubstituted (C1-C10) aminoalkyl oxy which were couple|bonded with
                                    C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl, an oxo and 2nd steroid,<lb/>A
                                    substituted or unsubstituted (C1-C10) aminoalkyl carboxy, a substituted or
                                    unsubstituted (C1-C10) aminoalkyl aminocarbonyl, H2N-HC(Q5)-C(O)-O-,
                                    H2N-HC(Q5)-C(O)-N(H)-, (C1-C10) azide alkyloxy,<lb/>(C1-C10)<lb/>Selecting from
                                    cyano alkyloxy, P. G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and (C1-C10)
                                    the group that consists of a guanidino alkyl carboxy, in Formula, Q5 is a side chain
                                    of arbitrary amino acids,<lb/>P. G. is amino protecting group.<lb/>and<lb/>At least
                                    2 of R1-R14 Substituted or unsubstituted (C1-C10) aminoalkyl oxy,<lb/>A substituted
                                    or unsubstituted (C1-C10) aminoalkyl carboxy, a substituted or unsubstituted
                                    (C1-C10) aminoalkyl aminocarbonyl,<lb/>H2N-HC-(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-,
                                    (C1-C10) azide alkyloxy (C1-C10) cyano alkyloxy,<lb/>It selects from P. G.
                                    -HN-C(Q5)-C(O)-O-, (C1-C10) cyano alkyloxy, P. G. -HN-C(Q5)-C(O)-O-, (C1-C10)
                                    guanidino alkyloxy, and (C1-C10) the group that consists of a guanidino alkyl
                                    carboxy;<lb/>Or it is pharmacologically acceptable salt thereof.
                                </p>
                                <p xml:id="_bb67360088" n="0006">The term &quot;condensed ring&quot; used in this
                                    specification,<lb/>Preferably it can become a heterocyclic ring or a carbocyclic
                                    ring.
                                </p>
                                <p xml:id="_bb67360090" n="0007">The term the &quot;saturation&quot; used in this
                                    specification points out condensed ring of the formula I which each atom in
                                    condensed ring is hydrogen as the valence of each atom is satisfy|filled, or is
                                    substituted.
                                </p>
                                <p xml:id="_bb67360091" n="0008">The term the &quot;unsaturation&quot; used in this
                                    specification points out condensed ring of the formula I by which the valence of
                                    each atom of condensed ring is not satisfy|filled with hydrogen or another
                                    substituent.<lb/>For example, the double bond of the carbon atom which adjoins in
                                    condensed ring can mutually be carried out.<lb/>The unsaturation can include
                                    deleting a pair of following at least 1 and making the valence of a carbocyclic-ring
                                    atom perfect by a double bond at least by these deletion;<lb/>R5, R9;R8, and R10;
                                    <lb/>And R13, R14, etc.
                                </p>
                                <p xml:id="_bb67360096" n="0009">The term &quot;unsubstitution&quot; used in this
                                    specification points out the part by which each atom is hydrogenated as the valence
                                    of each atom is satisfy|filled.
                                </p>
                                <p xml:id="_bb67360097" n="0010">The term &quot;halo&quot; used in this specification
                                    points out a halogen atom like a fluorine, chlorine, a bromine, or an iodine.
                                </p>
                                <p xml:id="_bb67360098" n="0011">Although H (glycine), methyl (alanine), -CH2-(C=O)-NH2
                                    (asparagine), -CH2-SH (cysteine), and -CH(OH) CH3 (threonine) are contained in the
                                    example of an amino acid side chain, it does not limit to these.
                                </p>
                                <p xml:id="_bb67360099" n="0012">An alkyl group is a branched or non-branched
                                    hydrocarbon which may be substituted or unsubstituted.<lb/>Isopropyl, sec-butyl,
                                    isobutyl, tert- butyl, sec -pentyl-, an isopentyl, tert- pentyl, isohexyl is
                                    contained in the example of a branched alkyl group.<lb/>A substituted alkyl group
                                    may have 1 and a 2, 3 or more substituent, they may be same or different, and each
                                    substitutes a hydrogen atom.<lb/>Substituents are a halogen (for example, F, Cl, Br,
                                    and I), hydroxyl, the protected hydroxyl, amino, the protected amino, a carboxy, the
                                    protected carboxy, cyano, methylsulfonyl amino, alkoxy, acyloxy, nitro, and lower
                                    haloalkyl.
                                </p>
                                <p xml:id="_bb67360103" n="0013">The term the &quot;substitution&quot; used in this
                                    specification points out 1, 2, and the part that has a 3 or more substituent by
                                    which it may be same or different and each substitutes a hydrogen atom.<lb/>Although
                                    a halogen (for example, F, Cl, Br, and I), hydroxyl, the protected hydroxyl, amino,
                                    the protected amino, a carboxy, the protected carboxy, cyano, methylsulfonyl amino,
                                    alkoxy, alkyl, aryl, aralkyl, acyloxy, nitro, and lower haloalkyl are contained in
                                    the example of a substituent, it does not limit to these.
                                </p>
                                <p xml:id="_bb67360105" n="0014">An aryl group is a C6-20 aromatic ring in which a ring
                                    is comprised with the carbon atom (For example, a C6-14, C6-10 aryl group).
                                    <lb/>
                                    Fluoromethyl, dichloro methyl, a trifluoromethyl, 1, 1- difluoroethyl, and 2, 2-
                                    dibromo ethyl is contained in the example of haloalkyl.
                                </p>
                                <p xml:id="_bb67360107" n="0015">An aralkyl group is group which has at least 1 alkyl or
                                    alkylene chain couple|bonded with at least 1 aryl ring and its ring and containing
                                    C6-C20.<lb/>An example of an aralkyl group is a benzyl group.
                                </p>
                                <p xml:id="_bb67360109" n="0016">A bonding group is a bivalent part used in order to
                                    combine another steroid, for example, the 2nd compound of the formula I, and the
                                    compound of a formula.<lb/>The example of a bonding group is (C1-C10) alkyloxy
                                    (C1-C10) alkyl.
                                </p>
                                <p xml:id="_bb67360111" n="0017">Many amino protecting groups are known at this
                                    technical field.<lb/>Generally, the kind of protecting group has stable it with
                                    respect to some subsequent reaction conditions in the other position of a compound,
                                    <lb/>Comprising:<lb/>It is not important as long as it can remove|eliminate at the
                                    suitable time, without exerting harmful|toxic influence with respect to the
                                    remainder of a molecule|numerator.<lb/>Furthermore, after substantial synthetic
                                    conversion is complete|finished, you may substitute a protecting group by another
                                    group.<lb/>The compound is contained in this invention when a certain compound
                                    differs from the compound of an indication evidently only within the point that the
                                    1 or more protecting group of the compound of an indication is substituted by a
                                    different protecting group.<lb/>The further Example and conditions are shown by T.
                                    W. green (T. W. Greene), &quot;protecting group (Protective Groups in Organic
                                    Chemistry) in an organic chemistry&quot;, and (the 1st edition, 1981 and 2nd
                                    plate|version|printing 1991).
                                </p>
                                <p xml:id="_bb67360118" n="0018">This invention includes the method of
                                    synthesize|combining the compound of the formula I, when at least 2 of R1-R14 is
                                    also selected from the group which consists independently of substituted or
                                    unsubstituted (C1-C10) aminoalkyl oxy.<lb/>This method includes the step which the
                                    compound of formula IV is made to contact:
                                    <formula n="0010" xml:id="_bb67360120">
                                        <figure xml:id="_bb67360121">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    In formula, at least 2 of R1-R14 is hydroxyl,<lb/>The remaining part on the
                                    condensed ring A, B, and C and D is defined to the formula I,<lb/>An electrophilic
                                    agent produces the alkyl ether compound of formula IV, and, in Formula, at least 2
                                    of R1-R14 is (C1-C10) alkyloxy.<lb/>The alkyl ether compound is converted into the
                                    amino precursor compound selected from the group which at least 2 of R1-R14 becomes
                                    independently from (C1-C10) azide alkyloxy and (C1-C10) cyano alkyloxy,<lb/>An amino
                                    precursor compound is reduce|restored and the compound of the formula I is formed.
                                </p>
                                <p xml:id="_bb67360126" n="0019">Although a 2-(2-bromo- ethyl) -1,3- dioxolane,
                                    2-iodoacetamide, the 2-chloro- acetamide, N-(2-bromo- ethyl) phthalimide,
                                    N-(3-bromo- propyl) phthalimide, and the allyl|allele bromide is contained in the
                                    electrophilic agent used in this method, it does not limit to these.<lb/>A
                                    preferable electrophilic agent is the allyl|allele bromide.
                                </p>
                                <p xml:id="_bb67360128" n="0020">This invention includes the method at least 2 of R1-R14
                                    also manufactures the compound of the formula I which is (C1-C10) guanido alkyloxy.
                                    <lb/>This method makes the compound of formula IV whose at least 2 of R1-R14 is
                                    hydroxyl contact an electrophilic agent.<lb/>At least 2 of R1-R14 includes producing
                                    the alkyl ether compound of formula IV which is (C1-C10) alkyloxy.<lb/>An allylether
                                    compound is converted into the amino precursor compound in which at least 2 of
                                    R1-R14 is independently selected from the group which consists of (C1-C10) azide
                                    alkyloxy and (C1-C10) cyano alkyloxy.<lb/>An amino precursor compound is
                                    reduce|restored and at least 2 of R1-R14 produces the aminoalkyl ether compound
                                    which is (C1-C10) aminoalkyl oxy.<lb/>When an aminoalkyl ether compound is made to
                                    contact with a guanidino production|generation electrophilic agent, the compound of
                                    the formula I will be produced|generated.
                                </p>
                                <p xml:id="_bb67360134" n="0021">The term the &quot;guanidino production|generation
                                    electrophilic agent&quot; used in this specification points out the electrophilic
                                    agent used in order to produce|generate the guanidino compound of the formula I.
                                    <lb/>The example of a guanidino production|generation electrophilic agent is
                                    HSO3-C(NH)-NH2.
                                </p>
                                <p xml:id="_bb67360136" n="0022">At least 2 of R1-R14 is H2 N-HC(Q5) -C(O)-O-, and this
                                    invention also includes the method Q5 manufactures the compound of the formula I
                                    which is a side chain of arbitrary amino acids.<lb/>A method makes the compound of
                                    formula IV whose at least 2 of R1-R14 is hydroxyl contact with the protected amino
                                    acid.<lb/>At least 2 of R1-R14 is P. G. -HN-HC(Q5)-C(O)-O-,<lb/>Q5 is a side chain
                                    of arbitrary amino acids,<lb/>P. G. includes the step which produces the amino acid
                                    compound which is an amino protecting group, and from which formula IV was
                                    protected.<lb/>When the protecting group of the protected amino acid compound
                                    remove|deviates, the compound of the formula I will be produced.
                                </p>
                                <p xml:id="_bb67360142" n="0023">This invention also contains an important
                                    pharmacological composition useful as an antibacterial agent, the bacteria
                                    sensitization agent with respect to other antibiotics, and a bacteria
                                    destruction-of-membrane agent.<lb/>A pharmacological composition can be used in
                                    order to treat the human and animal which have a bacterial infection.<lb/>The
                                    pharmacological composition can contain the effective dose of a steroid derivative
                                    in combination with individual or another antibacterial agent.
                                </p>
                                <p xml:id="_bb67360145" n="0024">this invention is also characterized by the compound or
                                    pharmacologically acceptable salt thereof of the formula I -- in formula,<lb/>The
                                    condensed ring A, B, and C and each of D are saturation, completeness, or partial
                                    unsaturation independently,<lb/>R4, R6, R7, R11 from R1, R12, R15, and each of R16,
                                    <lb/>Hydrogen, hydroxyl, substituted or unsubstituted (C1-C10) alkyl,<lb/>(C1-C10) A
                                    hydroxyalkyl (C1-C10) alkyloxy- (C1-C10) alkyl,<lb/>(C1-C10) Alkylamino- (C1-C10)
                                    alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl,<lb/>The bonding group,
                                    substituted or unsubstituted (C1-C10) aminoalkyl oxy, the substituted or
                                    unsubstituted (C1-C10) aminoalkyl carboxy which were couple|bonded with substituted
                                    or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl, an oxo, and
                                    2nd steroid,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl aminocarbonyl,
                                    the substituted or unsubstituted (C1-C5) aminoalkyl carboxamide, and Q5 are the side
                                    chains of an amino acid,<lb/>P. H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10)
                                    azide alkyloxy whose G. is an amino protecting group,<lb/>(C1-C10) It independently
                                    selects from cyano alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and
                                    (C1-C10) the group that consists of a guanidino alkyl carboxy,<lb/>When one of the
                                    condensed ring A, B, and C or the D is unsaturated in order that each of R5, R8, R9,
                                    R10, R13, and R14 may make perfect the valence of the carbon atom in the site|part,
                                    <lb/>it is deleted independently -- or hydrogen, hydroxyl, and substituted or
                                    unsubstituted (C1-C10) alkyl --<lb/>(C1-C10) A hydroxyalkyl (C1-C10) alkyloxy-
                                    (C1-C10) alkyl,<lb/>The bonding group, substituted or unsubstituted (C1-C10)
                                    aminoalkyl oxy which were couple|bonded with a substituted or unsubstituted (C1-C10)
                                    aminoalkyl, substituted or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl,
                                    C2-C6 alkynyl, an oxo, and 2nd steroid,<lb/>A substituted or unsubstituted (C1-C10)
                                    aminoalkyl carboxy, a substituted or unsubstituted (C1-C10) aminoalkyl
                                    aminocarbonyl, and Q5 are the side chains of an amino acid,<lb/>P.
                                    H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10) azide alkyloxy whose G. is an
                                    amino protecting group,<lb/>(C1-C10) It independently selects from cyano alkyloxy,
                                    P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and (C1-C10) the group that
                                    consists of a guanidino alkyl carboxy.<lb/>and<lb/>R17 is
                                    -CH(CH3)(CH2)3-NH-(CH2)7CH3,<lb/>At least two pieces to R1-R14 Substituted or
                                    unsubstituted (C1-C10) aminoalkyl oxy,<lb/>A substituted or unsubstituted (C1-C10)
                                    aminoalkyl carboxy, a substituted or unsubstituted (C1-C10) aminoalkyl
                                    aminocarbonyl,<lb/>It independently selects from H2N-HC(Q5)-C(O)-O-,
                                    H2N-HC(Q5)-C(O)-N(H)-, (C1-C10) azide alkyloxy (C1-C10) cyano alkyloxy,
                                    P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and (C1-C10) the group that
                                    consists of a guanidino alkyl carboxy.
                                </p>
                                <p xml:id="_bb67360167" n="0025">this invention is also characterized by the compound or
                                    pharmacologically acceptable salt thereof of the formula I -- in formula,<lb/>The
                                    condensed ring A, B, and C and each of D are saturation, completeness, or partial
                                    unsaturation independently,<lb/>R1, R2, R4, R6, R11, R15, R16 and each of R17,
                                    <lb/>
                                    Hydrogen, hydroxyl, substituted or unsubstituted (C1-C10) alkyl,<lb/>(C1-C10) A
                                    hydroxyalkyl (C1-C10) alkyloxy- (C1-C10) alkyl,<lb/>(C1-C10) Alkylamino- (C1-C10)
                                    alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl,<lb/>The bonding group,
                                    substituted or unsubstituted (C1-C10) aminoalkyl oxy, the substituted or
                                    unsubstituted (C1-C10) aminoalkyl carboxy which were couple|bonded with substituted
                                    or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl, an oxo, and
                                    2nd steroid,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl aminocarbonyl,
                                    the substituted or unsubstituted (C1-C5) aminoalkyl carboxamide, and Q5 are the side
                                    chains of an amino acid,<lb/>P. H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10)
                                    azide alkyloxy whose G. is an amino protecting group,<lb/>(C1-C10) It independently
                                    selects from cyano alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and
                                    (C1-C10) the group that consists of a guanidino alkyl carboxy,<lb/>R3, R7, and R12
                                    are -O-C(O)-(CH2)n-NH2 whose n is 3-5,<lb/>and<lb/>When one of the condensed ring A,
                                    B, and C or the D is unsaturated in order that each of R5, R8, R9, R10, R13, and R14
                                    may make perfect the valence of the carbon atom in the site|part,<lb/>it is deleted
                                    independently -- or hydrogen, hydroxyl, and substituted or unsubstituted (C1-C10)
                                    alkyl --<lb/>(C1-C10) A hydroxyalkyl (C1-C10) alkyloxy- (C1-C10) alkyl,<lb/>The
                                    bonding group, substituted or unsubstituted (C1-C10) aminoalkyl oxy which were
                                    couple|bonded with a substituted or unsubstituted (C1-C10) aminoalkyl, substituted
                                    or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl, an oxo, and
                                    2nd steroid,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl carboxy, a
                                    substituted or unsubstituted (C1-C10) aminoalkyl aminocarbonyl, and Q5 are the side
                                    chains of an amino acid,<lb/>P. H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10)
                                    azide alkyloxy whose G. is an amino protecting group,<lb/>(C1-C10) Cyano alkyloxy,
                                    P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy,<lb/>And (C1-C10) at least two
                                    pieces to R1-R14 independently selected from the group which consists of a guanidino
                                    alkyl carboxy are substituted or unsubstituted (C1-C10) aminoalkyl oxy and a
                                    substituted or unsubstituted (C1-C10) aminoalkyl carboxy,<lb/>A substituted or
                                    unsubstituted (C1-C10) aminoalkyl aminocarbonyl,<lb/>It independently selects from
                                    H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10) azide alkyloxy (C1-C10) cyano
                                    alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and (C1-C10) the group
                                    that consists of a guanidino alkyl carboxy.
                                </p>
                                <p xml:id="_bb67360189" n="0026">this invention is further characterized by the compound
                                    or pharmacologically acceptable salt thereof of the formula I -- in formula,<lb/>The
                                    condensed ring A, B, and C and each of D are saturation, completeness, or partial
                                    unsaturation independently,<lb/>R1, R2, R4, R6, R11, R15, R16 and each of R17,
                                    <lb/>
                                    Hydrogen, hydroxyl, substituted or unsubstituted (C1-C10) alkyl,<lb/>(C1-C10) A
                                    hydroxyalkyl (C1-C10) alkyloxy- (C1-C10) alkyl,<lb/>(C1-C10) Alkylamino- (C1-C10)
                                    alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl,<lb/>The bonding group,
                                    substituted or unsubstituted (C1-C10) aminoalkyl oxy, the substituted or
                                    unsubstituted (C1-C10) aminoalkyl carboxy which were couple|bonded with substituted
                                    or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl, an oxo, and
                                    2nd steroid,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl aminocarbonyl,
                                    the substituted or unsubstituted (C1-C5) aminoalkyl carboxamide, and Q5 are the side
                                    chains of an amino acid,<lb/>P. H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10)
                                    azide alkyloxy whose G. is an amino protecting group,<lb/>(C1-C10) It independently
                                    selects from cyano alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and
                                    (C1-C10) the group that consists of a guanidino alkyl carboxy,<lb/>R3, R7, and R12
                                    are -NH-C(O)-CH(Q5)-NH2 whose Q5 is a side chain of glycine, a side chain of
                                    alanine, or a side chain of a lysine,<lb/>and<lb/>When one of the condensed ring A,
                                    B, and C or the D is unsaturated in order that each of R5, R8, R9, R10, R13, and R14
                                    may make perfect the valence of the carbon atom in the site|part,<lb/>it is deleted
                                    independently -- or hydrogen, hydroxyl, and substituted or unsubstituted (C1-C10)
                                    alkyl --<lb/>(C1-C10) A hydroxyalkyl (C1-C10) alkyloxy- (C1-C10) alkyl,<lb/>The
                                    bonding group, substituted or unsubstituted (C1-C10) aminoalkyl oxy which were
                                    couple|bonded with a substituted or unsubstituted (C1-C10) aminoalkyl, substituted
                                    or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl, an oxo, and
                                    2nd steroid,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl carboxy, a
                                    substituted or unsubstituted (C1-C10) aminoalkyl aminocarbonyl, and Q5 are the side
                                    chains of an amino acid,<lb/>P. H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10)
                                    azide alkyloxy whose G. is an amino protecting group,<lb/>(C1-C10) It independently
                                    selects from cyano alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and
                                    (C1-C10) the group that consists of a guanidino alkyl carboxy,<lb/>At least two
                                    pieces to R1-R14 Substituted or unsubstituted (C1-C10) aminoalkyl oxy,<lb/>A
                                    substituted or unsubstituted (C1-C10) aminoalkyl carboxy, a substituted or
                                    unsubstituted (C1-C10) aminoalkyl aminocarbonyl,<lb/>It independently selects from
                                    H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10) azide alkyloxy (C1-C10) cyano
                                    alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and (C1-C10) the group
                                    that consists of a guanidino alkyl carboxy.
                                </p>
                                <p xml:id="_bb67360211" n="0027">this invention is also characterized by the compound or
                                    pharmacologically acceptable salt thereof of the formula I -- in formula,<lb/>The
                                    condensed ring A, B, and C and D are saturation, completeness, or partial
                                    unsaturation independently,<lb/>R1, R2, R4, R6, R11, R15, R16 and each of R17,
                                    <lb/>
                                    Hydrogen, hydroxyl, substituted or unsubstituted (C1-C10) alkyl,<lb/>(C1-C10) A
                                    hydroxyalkyl (C1-C10) alkyloxy- (C1-C10) alkyl,<lb/>(C1-C10) Alkylamino- (C1-C10)
                                    alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl,<lb/>The bonding group,
                                    substituted or unsubstituted (C1-C10) aminoalkyl oxy, the substituted or
                                    unsubstituted (C1-C10) aminoalkyl carboxy which were couple|bonded with substituted
                                    or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl, an oxo, and
                                    2nd steroid,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl aminocarbonyl,
                                    the substituted or unsubstituted (C1-C5) aminoalkyl carboxamide, and Q5 are the side
                                    chains of an amino acid,<lb/>P. H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10)
                                    azide alkyloxy whose G. is an amino protecting group,<lb/>(C1-C10) It independently
                                    selects from cyano alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and
                                    (C1-C10) the group that consists of a guanidino alkyl carboxy,<lb/>R3, R7, and R12
                                    are -NH-C(O)-(CH2)n-NH2 whose n is 1-5,<lb/>and<lb/>When one of the condensed ring
                                    A, B, and C or the D is unsaturated in order that each of R5, R8, R9, R10, R13, and
                                    R14 may make perfect the valence of the carbon atom in the site|part,<lb/>it is
                                    deleted independently -- or hydrogen, hydroxyl, and substituted or unsubstituted
                                    (C1-C10) alkyl --<lb/>(C1-C10) A hydroxyalkyl (C1-C10) alkyloxy- (C1-C10) alkyl,
                                    <lb/>The bonding group, substituted or unsubstituted (C1-C10) aminoalkyl oxy which
                                    were couple|bonded with a substituted or unsubstituted (C1-C10) aminoalkyl,
                                    substituted or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl,
                                    an oxo, and 2nd steroid,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl
                                    carboxy, a substituted or unsubstituted (C1-C10) aminoalkyl aminocarbonyl, and Q5
                                    are the side chains of an amino acid,<lb/>P. H2N-HC(Q5)-C(O)-O-,
                                    H2N-HC(Q5)-C(O)-N(H)-, (C1-C10) azide alkyloxy whose G. is an amino protecting
                                    group,<lb/>(C1-C10) It independently selects from cyano alkyloxy,
                                    P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and (C1-C10) the group that
                                    consists of a guanidino alkyl carboxy,<lb/>At least two pieces to R1-R14 Substituted
                                    or unsubstituted (C1-C10) aminoalkyl oxy,<lb/>A substituted or unsubstituted
                                    (C1-C10) aminoalkyl carboxy, a substituted or unsubstituted (C1-C10) aminoalkyl
                                    aminocarbonyl,<lb/>It independently selects from H2N-HC(Q5)-C(O)-O-,
                                    H2N-HC(Q5)-C(O)-N(H)-, -H2N-(CH2)n-C(O)-NH, (C1-C10) azide alkyloxy (C1-C10) cyano
                                    alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and (C1-C10) the group
                                    that consists of a guanidino alkyl carboxy.
                                </p>
                                <p xml:id="_bb67360233" n="0028">Further, this invention makes (a) 5(beta)- cholanoic
                                    acid 3,7,12- trion methyl ester contact with a hydroxylamine hydrochloride and
                                    sodium acetate, and forms the tri oxime (B):
                                    <formula n="0011" xml:id="_bb67360234">
                                        <figure xml:id="_bb67360235">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    and<lb/>(b) Method to manufacture compound (A) is included by making tri oxime (B)
                                    contact with NaBH4 and TiCl4, and manufacturing compound (A):
                                    <formula n="0012" xml:id="_bb67360237">
                                        <figure xml:id="_bb67360238">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                </p>
                                <p xml:id="_bb67360239" n="0029">This invention contains the compound which has a ring
                                    system of at least 4 condensed ring, and also has 5-7 atoms of this each rings.
                                    <lb/>
                                    A ring system has two surfaces and contains three chain|strands couple|bonded with
                                    the same surface.<lb/>This nitrogen-containing group is amino groups, such as a
                                    primary amino or a guanidino group, including the nitrogen-containing group into
                                    which each chain|strand was isolate|separated from the ring system with at least 1
                                    atom, for example.<lb/>Preferably, a compound has hydrophobic groups, such as a
                                    substitution (C3-10) aminoalkyl group couple|bonded with the steroid structure, the
                                    (C1-10) alkyloxy (C3-10) alkyl group, or (C1-10) the alkylamino (C3-10) alkyl group.
                                </p>
                                <p xml:id="_bb67360243" n="0030">For example, a compound has the formula V and three
                                    chain|strands which contain nitrogen-containing group in formula, are selected from
                                    R1-R4, R6, R7, R11, R12, R15, R16, R17, and R18 which are defined downward each
                                    independently.
                                    <formula n="0013" xml:id="_bb67360244">
                                        <figure xml:id="_bb67360245">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    In formula,<lb/>At least 2 of A, B, C, and the D is saturated,<lb/>When the ring A,
                                    B, and C and D form a ring system, the condensed ring A, B, and C and each of D are
                                    saturation, completeness, or partial unsaturation independently,<lb/>m, n, p, and q
                                    are 0 or 1 independently,<lb/>Each of R1 to R4, R6, R7, R11, R12, R15, R16, R17 and
                                    R18,<lb/>Hydrogen, hydroxyl, substituted or unsubstituted (C1-C10) alkyl,
                                    <lb/>
                                    (C1-C10) A hydroxyalkyl (C1-C10) alkyloxy- (C1-C10) alkyl,<lb/>(C1-C10) Alkylamino-
                                    (C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl,<lb/>The bonding
                                    group, substituted or unsubstituted (C1-C10) aminoalkyl oxy, the substituted or
                                    unsubstituted (C1-C10) aminoalkyl carboxy which were couple|bonded with substituted
                                    or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl, C2-C6 alkynyl, an oxo, and
                                    2nd steroid,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl aminocarbonyl,
                                    the substituted or unsubstituted (C1-C5) aminoalkyl carboxamide, and Q5 are the side
                                    chains of an amino acid,<lb/>P. H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10)
                                    azide alkyloxy whose G. is an amino protecting group,<lb/>(C1-C10) It independently
                                    selects from cyano alkyloxy, P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and
                                    (C1-C10) the group that consists of a guanidino alkyl carboxy,<lb/>When one of the
                                    condensed ring A, B, and C or the D is unsaturated in order that each of R5, R8, R9,
                                    R10, R13, and R14 may make perfect the valence of the carbon atom in the site|part,
                                    <lb/>it is deleted independently -- or hydrogen, hydroxyl, and substituted or
                                    unsubstituted (C1-C10) alkyl --<lb/>(C1-C10) A hydroxyalkyl (C1-C10) alkyloxy-
                                    (C1-C10) alkyl,<lb/>The bonding group, substituted or unsubstituted (C1-C10)
                                    aminoalkyl oxy which were couple|bonded with a substituted or unsubstituted (C1-C10)
                                    aminoalkyl, substituted or unsubstituted aryl, C1-C10 haloalkyl, a C2-C6 alkenyl,
                                    C2-C6 alkynyl, an oxo, and 2nd steroid,<lb/>A substituted or unsubstituted (C1-C10)
                                    aminoalkyl carboxy, a substituted or unsubstituted (C1-C10) aminoalkyl
                                    aminocarbonyl, and Q5 are the side chains of an amino acid,<lb/>P.
                                    H2N-HC(Q5)-C(O)-O-, H2N-HC(Q5)-C(O)-N(H)-, (C1-C10) azide alkyloxy whose G. is an
                                    amino protecting group,<lb/>(C1-C10) It independently selects from cyano alkyloxy,
                                    P.G.-HN-C(Q5)-C(O)-O-, (C1-C10) guanidino alkyloxy, and (C1-C10) the group that
                                    consists of a guanidino alkyl carboxy,<lb/>At least three of R1 to R4, R6, R7, R11,
                                    R12, R15, R16, R17 and R18.<lb/>Arrange|position in the same surface of a ring
                                    system and A substituted or unsubstituted (C1-C10) aminoalkyl,<lb/>Substituted or
                                    unsubstituted (C1-C10) aminoalkyl oxy, a substituted or unsubstituted (C1-C10)
                                    aminoalkyl carboxy,<lb/>A substituted or unsubstituted (C1-C10) aminoalkyl
                                    aminocarbonyl,<lb/>It independently selects from the substituted or unsubstituted
                                    (C1-C5) aminoalkyl carboxamide (C1-C10) guanidino alkyloxy, and (C1-C10) the group
                                    that consists of a guanidino alkyl carboxy.<lb/>Or it is pharmacologically
                                    acceptable its salt.<lb/>Preferably, at least 2 or at least 3 is 1 among m, n, p,
                                    and q.
                                </p>
                                <p xml:id="_bb67360271" n="0031">Although it does not desire to be restrict|limited to
                                    the specific theory, the steroid derivative as described in this specification acts
                                    as a bacteriostatic and a disinfectant|microbicide by couple|bonding with
                                    outside-film|membrane of a bacteria cell.<lb/>The consistency of a cell membrane is
                                    destroyed by interaction of a steroid derivative and a bacteria film|membrane, and,
                                    as a result, the death of a bacteria cell occurs by it.<lb/>Furthermore, the
                                    compound of this invention also acts so that bacteria may be sensitized with respect
                                    to other antibiotics.<lb/>At the density|concentration of the steroid derivative
                                    below the corresponding minimum bacteriostatic density|concentration, a
                                    derivative|guide_body makes bacteria a sensitivity more with respect to other
                                    antibiotics by making the permeability|transmittance of bacteria
                                    outside-film|membrane increase.<lb/>The measurement of :minimum inhibitory
                                    concentration (MIC), the measurement of minimal bactericidal concentration (MBC),
                                    and the capability for a steroid derivative to pull down MIC of other antibiotics,
                                    for example, an erythromycin, and a novobiocin are included in the measurement used
                                    in order to quantify an effect|action of the steroid derivative which acts on
                                    bacteria.
                                </p>
                                <p xml:id="_bb67360276" n="0032">An expert is expected to understand that the compound
                                    of a description hold|maintains the specific stereochemistry and electronic
                                    characterization which are recognized in steroid by this specification.<lb/>The term
                                    the &quot;same configuration&quot; used in this specification points out the
                                    substituent on the condensation steroid which has the same stereochemical
                                    directionality.<lb/>for example, a substituent R3, R7 and R12 -- all -- (beta)
                                    substitution -- or (alpha) substitution of is done.<lb/>C3, C7, the part R3, R7
                                    substituted by C12, and the configuration of R13 may become important for
                                    interaction with a cell membrane.
                                </p>
                                <p xml:id="_bb67360280" n="0033">Another situation<lb/>WHEREIN:<lb/>This invention is
                                    characterized by the several method which used the said compound.<lb/>For example,
                                    in order to treat the microorganisms infectious disease, the effective dose of the
                                    antibacterial composition containing such a compound is administered to a host (a
                                    human host is included).<lb/>The quantity of the compound which the compound itself
                                    may provide an antimicrobial effect|action and is administered in that case is
                                    enough to show an antimicrobial effect|action.<lb/>Or the further anti-microbial
                                    substance (for example, antibiotics) that should be conveyed to a microbial cell is
                                    included in an anti-microbial composition.<lb/>By making transport to a target cell
                                    easy, the compound can enhance the effectiveness of the further anti-microbial
                                    substance.<lb/>Depending on the case, an increase|augmentation may be substantial.
                                    <lb/>Especially important target microorganisms are bacteria (For example, bacteria
                                    which have a substantial quantity (&gt;40%) of the lipid A or a lipid A -like
                                    substance in Gram-negative bacteria at large or and outside-film|membrane).
                                    <lb/>
                                    Fungi, a virus, and the other microorganisms containing yeast may also be target
                                    living organism|raw_foods.
                                </p>
                                <p xml:id="_bb67360290" n="0034">In the other meaning of reinforcing the
                                    permeability|transmittance of a cell, this compound can be administered, in order to
                                    also introduce|transduce multiple types of substance which is different into a cell,
                                    especially said bacteria cell.<lb/>You may use this invention in order to
                                    introduce|transduce another substance like a macromolecule (for example, DNA without
                                    a vector) other than introduce|transducing an anti-microbial substance.
                                </p>
                                <p xml:id="_bb67360292" n="0035">This invention can be used in order to also manufacture
                                    the anti-microbial compositions (for example, disinfectant, an anti- sepsis agent,
                                    antibiotics, etc.) containing one of the said compounds.<lb/>These compositions are
                                    not limited to a pharmaceutical,<lb/>In order to control microbial (especially
                                    bacteria) proliferation, in the non-therapeutic meaning, you may use them locally.
                                    <lb/>For example, in the application which kills or controls microorganisms at the
                                    time of a contact, you may use them.
                                </p>
                                <p xml:id="_bb67360296" n="0036">Furthermore, in the another situation, this invention
                                    generally identifies an effective compound with respect to microorganisms by
                                    administering a candidate compound and the compound of this invention,<lb/>A
                                    candidate compound is characterized by the method of determining whether with
                                    respect to microorganisms, bacteriostatic or it has the toxic effect (For example,
                                    the anti- sepsis, a germicidal action, a disinfection effect|action, or an
                                    antibiotics effect|action).<lb/>Also in this case, the above bacteria are
                                    preferable.<lb/>Having an antimicrobial effect|action in the several meaning
                                    according to the situation of this invention is known,<lb/>However,<lb/>It becomes
                                    that having a certain effect|action with respect to the specific class of
                                    microorganisms like said bacteria is not shown, and possible to test candidate
                                    antimicrobial agent of a very wide range useful.<lb/>The test of the extensive
                                    antibiotics considered to be invalid with respect to Gram-negative bacteria or lipid
                                    A Mr. containing bacteria is attained according to this situation of this invention
                                    now so that it may describe in detail to the following.
                                </p>
                                <p xml:id="_bb67360303" n="0037">Furthermore, in the another situation, this invention
                                    is characterized by the composition included combining a substance like the
                                    antimicrobial described previously more in detail which should be
                                    introduce|transduced into a cell, and one of the said compounds.<lb/>You may mix a
                                    compound and the further substance with a pharmacologically acceptable carrier.
                                </p>
                                <p xml:id="_bb67360305" n="0038">It seems that the other characteristics or the
                                    advantage of this invention becomes clear from the claim of detailed description of
                                    the following related with a several aspect, and attachment.
                                </p>
                                <p xml:id="_bb67360306" n="0039">This invention includes the method of treating a
                                    steroid derivative producible according to the synthetic pathway of a description to
                                    this specification, and the test subject that has a disease carried by a bacterial
                                    infection by administering the effective dose of the pharmacological composition
                                    which contains the compound of an indication in this specification to a test
                                    subject.
                                </p>
                                <p xml:id="_bb67360307" n="0040">Detailed description<lb/>Generally, this invention
                                    provides the compound of said formula I.<lb/>The preparation method of the compound
                                    of the formula I, and MIC and MBC are described.<lb/>Membrane permeability is also
                                    measured and is described.<lb/>As shown below, in this invention, a useful compound
                                    contains the novel steroid derivative which shows bacteriostatic, a disinfection,
                                    and a bacteria sensitization characteristic.<lb/>This invention is contained in the
                                    formula as described in an attached claim, and an expert is expected to understand
                                    also attaining to the other compound which has the characteristics of description.
                                    <lb/>These characteristics are the following and it can determine them regarding
                                    each test compound using the assay described in literature.
                                </p>
                                <p xml:id="_bb67360314" n="0041">The precursor of the known compound used according to
                                    this invention and the novel compound of this invention can be purchased from Sigma
                                    Chemical Co., the Saint Louis; Aldrich company, and a Milwaukee; steroids &amp;
                                    research positive|plus company.<lb/>Generally the other compound of this invention
                                    is compoundable in accordance with a known method and the following method using the
                                    precursor which can be obtained.
                                </p>
                                <p xml:id="_bb67360316" n="0042">Although the compound of this invention contains the
                                    compound which has the amine or guanidine group covalently bonded to the steroid
                                    structure, for example, a cholic acid, it is not limited to these.<lb/>Another ring
                                    system, for example, 5-membered condensed ring, can be used.<lb/>The compound which
                                    has frame|skeleton which combined the 5-membered ring and the 6-membered ring is
                                    also contained in this invention.<lb/>The amine or the guanidine group is separated
                                    from frame|skeleton with one atom at least,<lb/>Preferably it is separated by two
                                    atoms, three pieces, or four pieces at least.<lb/>Frame|skeleton can be used in
                                    order to orient an amine or a guanidine group with a surface with steroid, i.e., a
                                    plane.<lb/>For example, schematic drawing which shows the compound which has a
                                    primary amino in a surface with frame|skeleton, i.e., a plane, is shown below.
                                </p>
                                <p xml:id="_bb67360323" n="0043">The biological activity of a compound can be determined
                                    by the standard method that the least concentration with which a change is not
                                    recognized by it at a predetermined period light absorbency (OD) is known to an
                                    expert like &quot;minimum inhibitory concentration (MIC)&quot; assay as described in
                                    a present Example recorded as MIC.<lb/>When a compound single-piece|unit is tested
                                    with respect to the control|contrast which lose|deletes a compound, an antimicrobial
                                    effect|action with a compound single-piece|unit will be determined.
                                </p>
                                <p xml:id="_bb67360325" n="0044">Or &quot;the fraction blockage|prevention
                                    density|concentration (FIC)&quot; is useful also in order to also determine the
                                    synergism at the time of combining between the compounds of this invention, or a
                                    compound with known antibiotics.<lb/>FIC performs the checkerboard titer measurement
                                    of a compound in one dimension of a microtiter plate,<lb/>It can determine by
                                    performing the checkerboard titer measurement of antibiotics in an another
                                    dimension.<lb/>FIC is calculated by investigating the influence of one antibiotics
                                    which acts on another MIC, and its contrary.<lb/>If FIC is 1, it will show that the
                                    influence of a compound is additional, and synergism will be shown if FIC is less
                                    than one.<lb/>Preferably, less than 0.5 FIC is obtained about synergism.<lb/>FIC can
                                    be determined as follows so that it may be used in this specification:
                                    <formula n="0001" xml:id="_bb67360332">
                                        <figure xml:id="_bb67360333">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Synergism with the other compound of a compound can be determined by this method.
                                    <lb/>For example, the substance which is not effective enough can be validated more
                                    with the compound of this invention with respect to specific bacteria by a safe
                                    dosage, and it enables it to use a substance with respect to the infectious disease
                                    of a novel category in this way generally.<lb/>With respect to several Gram-positive
                                    bacteria, although many especially existing antibiotics are effective, they are not
                                    adapted for the treatment of the present Gram-negative-bacteria infectious disease.
                                    <lb/>In the several case<lb/>WHEREIN:<lb/>Since it cannot enter into a cell,
                                    antibiotics may become invalid with respect to Gram-negative bacteria.<lb/>The
                                    compound of this invention may make permeability|transmittance increase so that
                                    antibiotics may become effective with respect to Gram-negative bacteria.
                                </p>
                                <p xml:id="_bb67360340" n="0045">Furthermore, a fraction blockage|prevention
                                    density|concentration is also used together with the compound of this invention, and
                                    the other compound which has unknown antimicrobial activity,<lb/>Or it is useful in
                                    order to determine the synergism at the time of using together with another
                                    compound, for example, the compound which test and shows antimicrobial activity.
                                    <lb/>For example, the compound of this invention may make permeability|transmittance
                                    increase, in order to validate the compound which lose|deletes anti- bacteria
                                    activity with respect to a microbe.<lb/>FIC can be used in order to also investigate
                                    about the other type of the substance which is introduce|transduced into a cell with
                                    the pervious|transmissive increase|augmentation compound of this invention and which
                                    is not recognized until now of activity.
                                </p>
                                <p xml:id="_bb67360344" n="0046">The present inventors do not intend that a certain
                                    single specific theory restrains, and such theory is not required for practice of
                                    this invention,<lb/>However,<lb/>One mechanism of action is lipid A interaction of a
                                    part [ a large number (normally three) ] which is the guanidino or amino part which
                                    is positive electric charge in physiological condition.<lb/>These parts
                                    leave|separate from the remaining general planes of a molecule|numerator, are
                                    extended, and copy the specific situation of a polymyxin structure in this way.
                                    <lb/>
                                    This point<lb/>WHEREIN:<lb/>The compound of this invention generally becomes useful
                                    so that the polymyxin may be useful.<lb/>For example, the polymyxin B (PMB) and
                                    polymyxin B nonapeptide (PMBN) are useful in order to permeabilize|transparentize a
                                    bacteria film|membrane.<lb/>Moreover regarding a systemic administartion, an expert
                                    is expected to understand the suitable toxicity screening which can select the
                                    compound which does not show toxicity by the dosage which enhances the
                                    permeability|transmittance of microorganisms.
                                </p>
                                <p xml:id="_bb67360353" n="0047">Like description, this invention also also includes the
                                    surface which a compound should treat in it, and not only a local but the
                                    non-therapeutic (anti- sepsis, disinfection, or the disinfection) application which
                                    contact.<lb/>The term of &quot;contacting&quot;,<lb/>Preferably, a compound inhibits
                                    and disinfects bacteria effectively, or it points out exposing bacteria to a
                                    compound so that an endotoxin (LPS) can be couple|bonded, or so that it can
                                    melt|dissolve, and Gram-negative-bacteria outside-film|membrane can be made into
                                    permeability|transmittance.<lb/>In order to test the bacteria sensitivity with
                                    respect to a compound, you may perform a contact in vitro by adding a compound to
                                    culture|cultivation bacteria, for example.<lb/>It is possible for a contact to
                                    administer a compound to the test subject who also has in-vivo, for example, a
                                    bacteria disorder|damage|failure like septic shock.<lb/>The quantity of a compound
                                    required since &quot;inhibition&quot;, the bacteriostasis &quot;which inhibits an
                                    effective dose&quot;, or a germicidal action is produced is pointed out.
                                    <lb/>
                                    Colon_bacillus|E._coli, Psudomonas aeruginosa (P. aeruginosa), an Enterobacter
                                    cloacae (E. cloacae), a Salmonella typhimurium (S. typhimurium), the Mycobacterium
                                    tuberculosis (M. Tuberculosis),<lb/>And Staphylococcus aureus (S. aureus) is
                                    contained in the bacteria example which may be inhibited.<lb/>In addition, the
                                    compound of this invention may be used in order to inhibit the antibiotic-resistant
                                    strain|stump|stock of microorganisms.
                                </p>
                                <p xml:id="_bb67360362" n="0048">The method of inhibiting bacteria proliferation may
                                    also further include addition of antibiotics for combined use or a synergistical
                                    medical treatment.<lb/>It seems that the suitable antibiotics administered are
                                    easily identified by the expert depending on a bacteria sensitivity typically like
                                    whether bacteria are a Gram negative or a Gram positive.<lb/>For the example of the
                                    specific class of the antibiotics tested on a synergistical medical treatment with
                                    the compound (as mentioned above) of this invention,<lb/>Aminoglycoside (for
                                    example, tobramycin), penicillin (for example, piperacillin),<lb/>A cephalosporin
                                    (for example, ceftazidime), fluoroquinolone (for example, ciprofloxacin), a
                                    carbapenem (for example, imipenem), tetracycline, and macrolide (For example, an
                                    erythromycin and a clarithromycin) are contained.<lb/>The method of inhibiting
                                    bacteria proliferation may also include adding antibiotics for combined use or a
                                    synergistical medical treatment further.<lb/>It seems that the suitable antibiotics
                                    administered are easily identified by the expert depending on a bacteria sensitivity
                                    like whether bacteria are Gram negatives typically or it is a Gram positive.
                                    <lb/>
                                    Aminoglycoside (An amikacin, gentamicin, kanamycin, netilmicin, the tobramycin,
                                    streptomycin, an azithromycin, a clarithromycin, an erythromycin, the erythromycin
                                    estolate / ethyl succinate,<lb/>The gluceptate / lacto bionate / stearate), a
                                    (beta)-lactam type|system|group (For example, penicillin G, the penicillin V, a
                                    methicillin, the nafcillin, an oxacillin, a cloxacillin, a dicloxacillin, an
                                    ampicillin, an amoxicillin, a ticarcillin, a carbenicillin, mezlocillin, azlocillin,
                                    and a piperacillin) like penicillin, or cephalosporin system<lb/>(For example, a
                                    cefalotin, a cefazolin, a cefaclor, a cefamandole,<lb/>A cefoxitin, a cefuroxime,
                                    cefonicid, a cefmetazole, a cefotetan,<lb/>Cefprozil, loracarbef, cefetamet, a
                                    cefoperazone, a cefotaxime, a ceftizoxime, a ceftriaxone, a ceftazidime, a cefepime,
                                    cefixime, cefpodoxime, and a cefsulodin) is contained in antibiotics typical besides
                                    said antibiotics, for example.<lb/>In the other class of antibiotics, for example A
                                    carbapenem type|system|group (for example, imipenem),<lb/>A monobactam
                                    type|system|group (for example, aztreonam), quinolone type (For example, a
                                    fleroxacin, the nalidixic acid, nofloxacin, ciprofloxacin, an ofloxacin, an
                                    enoxacin, lomefloxacin, and a cinoxacin), the tetracycline system (For example, a
                                    doxycycline, minocycline, tetracycline), and a glycopeptide type|system|group (for
                                    example, vancomycin, a teicoplanin) are contained.<lb/>Chloramphenicol, a
                                    clindamycin, a trimethoprim, the sulfamethoxazole, the nitrofurantoin, the rifampin,
                                    a mupirocin, and the polymyxin like PMB is contained in other antibiotics.
                                </p>
                                <p xml:id="_bb67360377" n="0049">Administration<lb/>A compound may administer the
                                    effective dose which inhibits not only bacteria proliferation but the proliferation
                                    of a virus or fungi to the arbitrary hosts containing animals other than a human or
                                    a human.<lb/>These compounds are useful as antimicrobial agent, an antiviral agent,
                                    and an antifungal.<lb/>A compound may administer the effective dose which inhibits
                                    not only bacteria proliferation but the proliferation of a virus or fungi to the
                                    arbitrary hosts containing animals other than a human or a human.<lb/>These
                                    compounds are useful as antimicrobial agent, an antiviral agent, and an antifungal.
                                </p>
                                <p xml:id="_bb67360382" n="0050">The compound of this invention can be parenterally
                                    administered by continuous injection|pouring which injected or on which it spent
                                    many hours.<lb/>a compound -- the inside of a local, an intravenous,
                                    intraperitoneal, an intramuscular, subcutaneous, and a cavity -- or it can
                                    administer percutaneously.<lb/>a microsphere -- or the percutaneous administration
                                    by oral administration by enclosure, aerosol transport in a lung, the iontophoresis,
                                    or the percutaneous electroporation of proteinoid is contained in the preferable
                                    method of conveying a compound.<lb/>The other administering method is known to an
                                    expert.
                                </p>
                                <p xml:id="_bb67360386" n="0051">The water of sterilization or a nonaqueous solution,
                                    suspension, and a milky lotion is contained in the preparation of parenteral
                                    administration of the compound of this invention.<lb/>The organic ester which the
                                    example of a nonaqueous solvent can inject like propylene glycol,
                                    polyethyleneglycol, a vegetable oil like olive oil, and an ethyl oleate is
                                    contained.<lb/>The water, alcohol/aqueous solution, the milky lotion, or suspension
                                    containing a physiological saline solution and a buffer culture medium is contained
                                    in an aqueous carrier.<lb/>A sodium chloride solution, Ringer's solution dextrose,
                                    dextrose sodium chloride, lactic acid addition (lactated) Ringer's solution, or
                                    fixed oil is contained in a parenteral solvent.<lb/>A liquid, a supplement, the
                                    electrolyte adjuvant (it is like the solution based on Ringer's solution dextrose),
                                    etc. are contained in an intravenous solvent.<lb/>For example, preservatives, such
                                    as antimicrobial agent, an antioxidant, a chelating agent, and an inert gas, and
                                    another additive may also exist.
                                </p>
                                <p xml:id="_bb67360392" n="0052">This invention to the test subject who shows the
                                    symptom of the sepsis or has a risk of developing the symptoms of the sepsis,
                                    <lb/>
                                    Endotoxemia and the septic shock (sepsis) related disorder|damage|failure including
                                    administering the therapeutic effective dose of the compound of this invention, or
                                    the method of treating or relieve|moderating 1 or several symptom of the sepsis is
                                    provided.<lb/>It points out that the term of &quot;relieve|moderating&quot;
                                    decreases the symptom of the disorder|damage|failure which should be treated, or
                                    reduces.<lb/>Symptom relevant to the transient increase in a blood level of TNF like
                                    heat_generation|fever, a blood pressure decrease, the neutropenia, a leukopenia, the
                                    thrombocytopenia, a disseminated intravascular coagulation disease, adult
                                    respiratory distress syndrome, an impact|shock, and multiple organ failure is
                                    contained in such symptom relieve|moderated.<lb/>It has a risk of toxemia like the
                                    endotoxemia which occurs owing to the Gram-negative-bacteria infectious disease,
                                    snake-venom poisoning, or liver failure to the patient who requires such a
                                    treatment, for example, or the patient suffered from them is contained in him.
                                    <lb/>
                                    Furthermore, the patient who has Gram-positive bacteria, a virus, or a fungal
                                    infection may show the symptom of the sepsis, and a favor may be obtained by this
                                    specification by the treatment method of a description.<lb/>Especially the patient
                                    by whom a favor is got more by the method of this invention,<lb/>He is the patient
                                    suffered from the infectious disease by colon_bacillus|E._coli, the influenza B
                                    microbe (Haemophilus influenzae B), Neisseria meningitidis (Neisseria meningitidis),
                                    a Streptococcus (staphylococci), or the pneumococcus (pneumococci).<lb/>The patient
                                    who has gun damage, a kidney or liver failure, an external injury, a burn,
                                    immunocompromised (HIV), a hematogenous neoplasm, multiple myeloma, a castor man
                                    disease, or the cardiac myxoma is contained in a patient with the risk of the
                                    sepsis.
                                </p>
                                <p xml:id="_bb67360401" n="0053">Furthermore, a compound may be incorporated in the
                                    biodegradable polymer which enables continuous discharge|release, and that a polymer
                                    is conveyed may also embed, the vicinity, for example, the bacterial infection
                                    site|part, of a desirable place.<lb/>A biodegradable polymer and its use are
                                    described in detail by Brem and J. Neurosurg. 74:441-446(1991).
                                </p>
                                <p xml:id="_bb67360403" n="0054">As mentioned above, this invention provides the
                                    pharmaceutical preparation which has an effective dose of the compound of the
                                    formula I, in order to treat the patient who has a bacterial infection.<lb/>When the
                                    effective dose of a compound is administered to a patient so that it may be used in
                                    this specification,<lb/>Bacteria proliferation is inhibited,<lb/>It defines as a
                                    quantity of a compound which disinfects a bacteria cell and which lose|disappears a
                                    bacterial infection completely in the patient who sensitized or treated bacteria
                                    with respect to other antibiotics.<lb/>It is thought that the dosage of a
                                    composition is dependent on the clinical factor of others like the body weight of
                                    the disease which should be treated, the specific derivative|guide_body to be used,
                                    and a patient, a disease, and the administration route of a compound.<lb/>However,
                                    in oral administration to a human, it is a dosage of a 0.01 - 100 mg/kg /day,
                                    <lb/>
                                    Preferably 0.01 - 1 mg/kg /day is generally enough.<lb/>It is thought that an
                                    effective dosage also changes according to the possibility of use of an
                                    administration route and an excipient|filler and combined use of the other
                                    therapeutic treatment containing another antibacterial agent so that it may be
                                    recognized by the expert.
                                </p>
                                <p xml:id="_bb67360411" n="0055">For example, in order that the term the &quot;therapeutic
                                    effective dose&quot; used in this specification for the treatment of endotoxemia may
                                    decrease reaction with respect to a test subject's LPS and may decrease the symptom
                                    of the sepsis, it is sufficient quantity.<lb/>Therefore, the term &quot;therapeutic
                                    effectiveness&quot; prevents a significant increase clinically [ the plasma
                                    concentration of TNF ],<lb/>Preferably it is made to reduce by at least 50%.
                                    <lb/>
                                    Sufficient quantity is included in order to make it reduce by 90% more preferably.
                                    <lb/>Since a desired effect|action is produced, the dosage range in the case of
                                    administering a compound is a quantity large enough.<lb/>Generally, a dosage changes
                                    with the grades of the infectious disease by age, a state, sex and the bacteria in a
                                    patient, or said other substance, and will be determined by the expert.<lb/>When
                                    there exists a certain contraindication, each doctor can adjust a dosage.<lb/>Also
                                    in any phenomenon, the effectiveness of a treatment can be determined by monitoring
                                    the level of LPS and TNF in a patient.<lb/>The reduction|decrease of the serum
                                    density|concentration of LPS and TNF should be correlated with a patient's
                                    recovery|restoration.
                                </p>
                                <p xml:id="_bb67360420" n="0056">Furthermore, there exists a risk of the sepsis or the
                                    patient who shows the symptom can treat by said method of further including
                                    administering therapeutic administration of a compound, the inhibitor of TNF,
                                    antibiotics, or both substantially simultaneously.<lb/>For example, the symptom of
                                    the sepsis can be prevented or relieve|moderated if it intervenes in the role of TNF
                                    in the sepsis directly or indirectly by using an anti- TNF antibody and/or a TNF
                                    antagonist.<lb/>As Tracey (Nature 330:662, 1987) describes, it is especially
                                    preferable to use an anti- TNF antibody like the monoclonal antibody which has TNF
                                    specificity as an active component.
                                </p>
                                <p xml:id="_bb67360423" n="0057">The patient who shows the symptom of the sepsis may
                                    treat with antibiotics other than a treatment with a compound.<lb/>Aminoglycoside
                                    like gentamicin, (beta)-lactam like penicillin, a cephalosporin, or the antibiotics
                                    described until now is contained in typical antibiotics.<lb/>Therefore, the
                                    preferable treatment method of this invention includes administering the therapeutic
                                    effective dose of a cation compound substantially simultaneously with administration
                                    of the amount of disinfections of antibiotics.<lb/>Preferably, administration of a
                                    compound occurs within about 48 hours,<lb/>Preferably it is less than about 2 to 8
                                    hours,<lb/>Most preferably, it occurs substantially simultaneously with
                                    administration of antibiotics.
                                </p>
                                <p xml:id="_bb67360429" n="0058">On this specification and the term &quot;the amount of
                                    disinfections&quot; point out quantity sufficient since a bactericidal blood level
                                    is reached in the patient who receives a treatment.<lb/>The amount of disinfections
                                    of the antibiotics which administer to a human and are generally recognized to be
                                    safe is known at this technical field,<lb/>According to specific antibiotics and the
                                    type of a bacterial infection treated, it changes known by this technical field.
                                </p>
                                <p xml:id="_bb67360432" n="0059">You may also use them as the preservative or
                                    sterilization agent of the material which is easy to receive microorganisms or virus
                                    contamination for the antibiotics of a compound, an antibacterial agent, and
                                    antiviral property.<lb/>The compound of this invention can be utilized as an
                                    antibacterial agent of the broad spectrum orient|assigned with respect to various
                                    specific applications.<lb/>When such a application used together with a
                                    single-piece|unit or antibacterial food additive like a lysozyme with respect to the
                                    microorganisms containing Salmonella (Salmonella), Yersinia (Yersinia), and Shigella
                                    and it confirms that it is effective,<lb/>As the preservative in a processed food;
                                    <lb/>A compound can be used in order to disinfect (Pseudomonas, a Streptococcus
                                    (Streptococcus)) and the odor production|generation microorganisms (Micrococcus
                                    (Micrococci)) as a local agent.<lb/>The relative effectiveness of the compound of
                                    this invention regarding the described application can be easily determined by an
                                    expert by determining the sensitivity of the microorganisms with respect to one of a
                                    compound.
                                </p>
                                <p xml:id="_bb67360438" n="0060">This invention may become effective also to the other
                                    microorganisms which have a hydrophobic mantle, although the mantle mainly makes the
                                    target the classic gram-negative dyeing|staining bacteria containing a substantial
                                    quantity of the lipid A.<lb/>For example, Mycobacterium (mycobacterium) genus has a
                                    coating of a square shape protective outer side,<lb/>When the compound of this
                                    invention is used together with antibiotics, effectiveness may be enhanced with
                                    respect to the Mycobacterium (mycobacterium) infectious disease including
                                    tuberculosis.<lb/>In that case, a compound can be administered to a nostril with
                                    either of the several known techniques (attraction|suction).
                                </p>
                                <p xml:id="_bb67360442" n="0061">The introduction|transduction to the microorganisms of
                                    very various substances may be increase|augmented separately from an antimicrobial
                                    effect|action by the permeability|transmittance provided with a compound.<lb/>For
                                    example, you may use a compound in order to increase|augment the microorganisms of a
                                    macromolecule like DNA or RNA, especially the introduction|transduction to
                                    Gram-negative bacteria.<lb/>In that case, when transfecting microorganisms, in order
                                    to package a nucleic acid, it may be necessary to use the conventional vector (for
                                    example, phage).<lb/>It seems that the conditions and technique which
                                    introduce|transduce such a macromolecule into microorganisms at microorganisms using
                                    the compound of this invention are a routine in almost all cases.
                                </p>
                                <p xml:id="_bb67360446" n="0062">The formulation suitable for [ for an oral, the rectum,
                                    a nostril, a local (transbuccal and hypoglottis), intravaginal, or parenteral
                                    (Inside of subcutaneous, an intramuscular, an intravenous, intradermal, intraocular,
                                    air_pipe|trachea, and a dura|hard film) administration ] is contained in a
                                    formulation.<lb/>A unit dosage form may be simply used for a formulation, and it may
                                    prepare it with the conventional pharmacological technique.<lb/>Such a technique
                                    includes the step of making an active component, a pharmacological support|carrier,
                                    or an excipient|filler associating.<lb/>Generally, a formulation makes an active
                                    component uniformly and fully associate with a liquid support|carrier, a fine powder
                                    solid support|carrier, or both, and if required for the next, it will be prepared by
                                    shape|molding into a product.
                                </p>
                                <p xml:id="_bb67360450" n="0063">The formulation of this invention suitable for oral
                                    administration is a separate unit like a capsule, the trochiscus, or a tablet in
                                    which each contains a quantified active component;<lb/>A powder agent or granule;
                                    <lb/>The solution or suspension in an aqueous liquid or a nonaqueous liquid;<lb/>Or
                                    an oil-in-water type liquid milky lotion or a water-in-oil type milky lotion, bolus,
                                    etc. may be sufficient.
                                </p>
                                <p xml:id="_bb67360454" n="0064">You may selectively produce a tablet by compression or
                                    shaping|molding with 1 or several auxiliary|assistant component.<lb/>In the suitable
                                    machine, the compressed tablet selectively mixes an active component of a free flow
                                    type|mold like a powder or a granule with binder, a lubrication agent, an inactive
                                    diluent, a preservative, surface activity, or a dispersing agent,<lb/>You may
                                    prepare by compressing.<lb/>You may produce a shaping|molding tablet by
                                    shape|molding the mixture of the powder compound made to become wet with an inactive
                                    liquid diluent in the suitable machine.<lb/>A tablet may selectively put in a
                                    coating or a notch, and it may formulate it so that late|slow or continuous
                                    discharge|release of an active component may be obtained.
                                </p>
                                <p xml:id="_bb67360459" n="0065">In the formulation suitable for a local administration
                                    in an opening|mouth, they are an aroma base and the trochiscus which contains a
                                    component in a cane sugar and acacia, or a gum tragacanth normally;<lb/>Pastille
                                    which contains an active component in an inactive base like gelatin and glycerol or
                                    a cane sugar, and acacia;<lb/>And the mouthwash fluid containing the component
                                    administered in the suitable liquid support|carrier is contained.
                                </p>
                                <p xml:id="_bb67360462" n="0066">The ointment, the cream, gel, and paste containing the
                                    component administered in a pharmacologically acceptable carrier may be used for the
                                    formulation suitable for the local administration to skin.<lb/>A preferable local
                                    transit system is the percutaneous|transdermal patch containing the component which
                                    should be administered.
                                </p>
                                <p xml:id="_bb67360464" n="0067">You may show the formulation for rectal administration
                                    as a suppository by the suitable base containing a cocoa butter or salicylate.
                                </p>
                                <p xml:id="_bb67360465" n="0068">The coarse-powder which is a range whose particle
                                    diameter is 20-500 microns is contained in the formulation suitable for the
                                    intranasal administration whose support|carrier is solid,<lb/>This is administered
                                    so that nose suction|inhalation may be performed in it, namely, so that it may be
                                    rapidly suck|inhaled through a nostril from the powder container hold|maintained
                                    near the nose.<lb/>The aqueous solution or the oleaginous solution of an active
                                    component is contained in the suitable formulation which is a liquid for a
                                    support|carrier to administer, for example as nose spray or a nasal drops.
                                </p>
                                <p xml:id="_bb67360468" n="0069">An included pessary like the support|carrier by which
                                    the suitable thing is known for this technical field in addition to the active
                                    component, a tampon, cream, a gel, a paste, a foam|form, or the spray formulation
                                    may be used for the formulation suitable for intravaginal administration.
                                </p>
                                <p xml:id="_bb67360469" n="0070">The water and nonaqueous sterilization injection
                                    solution which may also contain in the formulation suitable for parenteral
                                    administration the antioxidant, the buffering agent or other bacteriostatic, and
                                    solute which make isotonic the blood and formulation of the recipient who is
                                    planning;<lb/>And the water and nonaqueous sterilization suspension which may also
                                    contain a suspending agent and strong agent are included.<lb/>The form of a unit
                                    dosage or a multidose container, for example, the sealed ampule, and a vial may be
                                    sufficient as a formulation,<lb/>You may preserve|save in the freeze-dry (it
                                    lyophilized|freeze-dried) state which only adds a liquid support|carrier, for
                                    example, water, for injection just before use.<lb/>You may prepare a quick
                                    preparation injection solution and suspension from the sterilization powder,
                                    granule, and tablet of the kind described previously.
                                </p>
                                <p xml:id="_bb67360474" n="0071">A preferable unit administration formulation is a
                                    formulation including the daily dose of the administered component previously
                                    referred in this specification or a unit, a 1 day-worth rate dosage, or its suitable
                                    fraction.
                                </p>
                                <p xml:id="_bb67360475" n="0072">Component,<lb/>Especially, it may add to said
                                    component, and the formulation of this invention may also contain a customary other
                                    substance by this technical field regarding the type of this formulation, for
                                    example, the formulation suitable for oral administration may also include a
                                    artificial flavoring.
                                </p>
                                <p xml:id="_bb67360477" n="0073">In the meaning that it is the active component and
                                    compatibility of a formulation (And preferably it can be stabilized.), the
                                    support|carrier in a pharmacological composition must be &quot;possible [ an
                                    acceptance|permission ]&quot;, and must be a thing which should be treated and which
                                    is not harmful|toxic with respect to a test subject.
                                </p>
                                <p xml:id="_bb67360478" n="0074">It is thought that previous description makes this
                                    invention possible appropriately without performing the further efforts.
                                    <lb/>
                                    Therefore, the following specific aspects are mere description,<lb/>Comprising:
                                    <lb/>
                                    It is not interpreted as in any event restrict|limiting the remainder of this
                                    indication.<lb/>All the publications which were referred to this specification and
                                    including a patent are incorporated in this specification as a reference.
                                </p>
                                <p xml:id="_bb67360483" n="0075">Examples 1-13 show the typical synthesis|combination of
                                    the compounds 1-302 so that it may illustrate to the schemes 1-13.<lb/>Example 14
                                    represents the other compound of the formula I compoundable using the reaction
                                    scheme of a description and resemblance|analogue to a known start material and this
                                    specification.<lb/>For example, C3- to which the hydroxyl group of a cholic acid
                                    originates in &quot;bile acid of C and others (Hsieh),<lb/>It is convertible for an
                                    amine group by the synthesis|combination of C12- and C24-substituted amino steroid,
                                    and DNA binding characteristic (Synthesis and DNA Binding Properties of C3-, C12-,
                                    and C24- substituted Amino-Steroids Derived from Bile Acids)&quot;, a Biorganic and
                                    Medical Chemistry, 1995, 6 volume and the method of 823-838.<lb/>Example 15
                                    represents MIC and a MCB test, and Example 16 represents that the compound of the
                                    formula I can reduce MIC of other antibiotics.
                                </p>
                                <p xml:id="_bb67360488" n="0076">
                                    <formula n="0014" xml:id="_bb67360489">
                                        <figure xml:id="_bb67360490">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Preparation of the scheme 1. compounds 1, 2, 4, and 5<lb/>Reagent (the reaction
                                    yield is shown in a bracket|parenthesis): a LiAlH4 (98 %).<lb/>b) A trityl chloride,
                                    Et3N, DMF(70%).<lb/>c) An allyl bromide, NaH, THF (96 %).<lb/>d) O3, CH2Cl2,
                                    MeOH:Me2S:NaBH4 (95 %).<lb/>e) 9-BBN, THF:H2O2, NaOH (80 %).<lb/>f) MsCl, CH2Cl2,
                                    and Et3N (78 %, 82 %).<lb/>g) NaN3, DMSO(19 is directly carried to 23 66% regarding
                                    20.).<lb/>h) TsOH, MeOH (being 94 % and the whole from 19 94 %).<lb/>i) MsCl,
                                    CH2Cl2, and Et3N (99 %, 97 %).<lb/>j) N-benzyl methylamine (95 %, 96 %).<lb/>k)
                                    LiAlH4, THF (95 %, 99 %).<lb/>l) NH2(CH) SO3, MeOH (91 %, 89 %).
                                </p>
                                <p xml:id="_bb67360503" n="0077">
                                    <formula n="0015" xml:id="_bb67360504">
                                        <figure xml:id="_bb67360505">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Preparation of the scheme 2. compound 3<lb/>Reagent (the reaction yield is shown in
                                    a bracket|parenthesis): a KCN, DMSO;MeOH, TsOH (92 %).<lb/>(b)MsCl, Et3N,
                                    CH2Cl2;BnMeNH(88%).<lb/>c) LiAlH4, AlCl3, THF (50 %).
                                </p>
                                <p xml:id="_bb67360509" n="0078">
                                    <formula n="0016" xml:id="_bb67360510">
                                        <figure xml:id="_bb67360511">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Preparation of the schemes 3.6 and 7<lb/>Reagent (the reaction yield is shown in a
                                    bracket|parenthesis): a dicyclohexylcarbodiimide, the N-hydroxy succinimide, a
                                    methylphenyl amine, CH2Cl2, MeOH(85%).<lb/>b) LiAlH4, THF (82 %).<lb/>c) A
                                    dicyclohexylcarbodiimide, a dimethylamino pyridine, Boc-glycine, CH2Cl2(68%).<lb/>d)
                                    A dicyclohexylcarbodiimide, a dimethylamino pyridine, Boc-(beta) alanine,
                                    CH2Cl2(72%).<lb/>e) HCl, a dioxane (- 100 % - 100 %).
                                </p>
                                <p xml:id="_bb67360517" n="0079">
                                    <formula n="0017" xml:id="_bb67360518">
                                        <figure xml:id="_bb67360519">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 4<lb/>Reagent (the reaction yield is shown in a bracket|parenthesis): a DIAD
                                    and Ph3P, p-nitrobenzoic acid, THF(85%);NaOH, MeOH(85%).<lb/>b) An allyl bromide,
                                    NaH, THF (79 %).<lb/>c) O3, CH2Cl2, MeOH;<lb/>Me2S: NaBH4 (65 %).<lb/>d) MsCl,
                                    CH2Cl2, and Et3N (86 %).<lb/>e) NaN3, DMSO (80 %).<lb/>f) TsOH, MeOH (94 %).<lb/>g)
                                    MsCl2, CH2Cl2, an Et3N:N-benzyl methylamine (93 %).<lb/>g) LiAlH4, THF (94 %).
                                </p>
                                <p xml:id="_bb67360529" n="0080">
                                    <formula n="0018" xml:id="_bb67360530">
                                        <figure xml:id="_bb67360531">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    The synthesis|combination of the scheme 5. compounds 9 and 10<lb/>Reagent (the
                                    reaction yield is shown in a bracket|parenthesis): a NaH, a bromination ocryl,
                                    DMF(80%);LiAlH4, THF(60%).<lb/>b) LiAlH4, THF (60 %).
                                </p>
                                <p xml:id="_bb67360534" n="0081">
                                    <formula n="0019" xml:id="_bb67360535">
                                        <figure xml:id="_bb67360536">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 6<lb/>Reagent (the reaction yield is shown in a bracket|parenthesis): a
                                    ethylene glycol, TsOH, benzene (- 100 %).<lb/>b) NaOH, MeOH (96 %).<lb/>c) An allyl
                                    bromide, NaH, THF (90 %).<lb/>d) 9-BBN, THF;<lb/>H2O2, NaOH (55 %).<lb/>e) PPTS,
                                    acetone, H2O (98 %).<lb/>f) MsCl and Et3N, CH2Cl2;<lb/>NaN3, DMSO (88 %).<lb/>g)
                                    LiAlH4, THF (69 %).
                                </p>
                                <p xml:id="_bb67360546" n="0082">
                                    <formula n="0020" xml:id="_bb67360547">
                                        <figure xml:id="_bb67360548">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 7<lb/>Reagent (the reaction yield is shown in a bracket|parenthesis): a
                                    methanesulfonyl chloride, Et3N, CH2Cl2;NaBr, DMF(97%).<lb/>b) 23, NaH, DMF (52 %).
                                    <lb/>c) LiAlH4, THF (76 %).
                                </p>
                                <p xml:id="_bb67360552" n="0083">
                                    <formula n="0021" xml:id="_bb67360553">
                                        <figure xml:id="_bb67360554">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 8<lb/>Reagent (the reaction yield is shown in a bracket|parenthesis): a NaH,
                                    DMF, CH3I, CH3(CH2)2Br, CH3(CH2)4 Br<lb/>or<lb/>CH3(CH2)7Br(85-90%).<lb/>b) LiAlH4,
                                    THF (55-70%).
                                </p>
                                <p xml:id="_bb67360559" n="0084">
                                    <formula n="0022" xml:id="_bb67360560">
                                        <figure xml:id="_bb67360561">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 9<lb/>Reagent (the reaction yield is shown in a bracket|parenthesis): a urea-
                                    hydrogen peroxide compound material, a trifluoroacetic acid anhydride, CH2Cl2(55%).
                                    <lb/>b) NaOH, MeOH;LiAlH4, THF (43 %).
                                </p>
                                <p xml:id="_bb67360564" n="0085">
                                    <formula n="0023" xml:id="_bb67360565">
                                        <figure xml:id="_bb67360566">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 10<lb/>Reagent (the reaction yield is shown in a bracket|parenthesis): a O3,
                                    CH2Cl2, MeOH;<lb/>Me2S;<lb/>NaBH4 (76 %).<lb/>b) NaOH, MeOH;<lb/>TrCl and Et3N,
                                    DMAP, DMF;<lb/>An allyl bromide, NaH, and THF (64 %).<lb/>c) 9-BBN, THF;<lb/>H2O2
                                    and NaOH (93 %).<lb/>d) MsCl and Et3N, CH2Cl2;<lb/>NaN3, DMSO;<lb/>TsOH, MeOH,
                                    CH2Cl2 (94 %).<lb/>e) LiAlH4, THF (71 %).<lb/>f) O-NO2C6H4SeCN, Bu2P, THF;<lb/>H2O2
                                    (36 %).<lb/>g) O3, CH2Cl2, MeOH;<lb/>Me2S;<lb/>LiAlH4, THF (68 %).
                                </p>
                                <p xml:id="_bb67360584" n="0086">
                                    <formula n="0024" xml:id="_bb67360585">
                                        <figure xml:id="_bb67360586">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 11<lb/>Reagent (the reaction yield is shown in a bracket|parenthesis): a
                                    BOC-glycine or BOC-alanine, DCC, DMAP, CH2Cl2(60%, 94%).<lb/>b) 4M HCl in a dioxane
                                    (74 %, 71 %).
                                    <formula n="0025" xml:id="_bb67360589">
                                        <figure xml:id="_bb67360590">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    <formula n="0026" xml:id="_bb67360591">
                                        <figure xml:id="_bb67360592">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                </p>
                                <p xml:id="_bb67360593" n="0087">
                                    <formula n="0027" xml:id="_bb67360594">
                                        <figure xml:id="_bb67360595">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 12<lb/>Reagent (the reaction yield is shown in a bracket|parenthesis): a
                                    BOC-glycine, BOC-alanine or a bis|screw BOC lysine, DCC, DMAP, CH2Cl2.<lb/>b) LiOH,
                                    THF, and MeOH (two steps of 71-85%).<lb/>c) 4M HCl in a dioxane (- 100 %).
                                    <formula n="0028" xml:id="_bb67360599">
                                        <figure xml:id="_bb67360600">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                </p>
                                <p xml:id="_bb67360601" n="0088">
                                    <formula n="0029" xml:id="_bb67360602">
                                        <figure xml:id="_bb67360603">
                                            <graphic url="/1"/>
                                        </figure>
                                    </formula>
                                    Scheme 13<lb/>Reagent: a NH2OH-HCl, AcONa, and EtOH (97 %).<lb/>b) NaBH4, TiCl4,
                                    glyme|Grimm (33 %).
                                </p>
                                <p xml:id="_bb67360606" n="0089">The synthesis|combination of the compounds 1-302
                                    <lb/>
                                    Whole:<lb/>&lt;1&gt;H and &lt;13&gt;C NMR spectrum are recorded on Varian Gemini
                                    2000 (200 MHz), the Varian unity 300 (300 MHz), or Varian VXR 500 (500 MHz)
                                    spectrophotometer,<lb/>It was based on TMS, residual CHCl3(&lt;1&gt;H), CDCl3(&lt;13&gt;C),
                                    residual CHD2OD (1H), or CD3OD (13C).<lb/>IR spectrum was recorded by the
                                    Perkin-Elmer 1600 FTIR apparatus.<lb/>Mass-spectrum data were obtained on the JOEL
                                    SX 102A spectrophotometer.<lb/>THF was dried on Na/benzophenone before use, and
                                    CH2Cl2 was dried on CaH2.<lb/>The other reagent and the solvent were purchased and
                                    were used with the undiluted|stock solution.
                                </p>
                                <p xml:id="_bb67360614" n="0090">Example 1<lb/>Compound 13:<lb/>Cholic-acid methyl
                                    (30.67 g, 72.7mmol) and LiAlH4(4.13g, 109mmol) which use anhydrous THF (600 mL) as a
                                    solvent were added to a 1 liter round bottom flask.<lb/>After recirculate|refluxing
                                    for 48 hours, the precipitation acquired by inject|pouring the saturated aqueous
                                    solution (100 mL) of Na2SO4 slowly was filtered, and Heat|fevers THF and MeOH
                                    wash|cleaned.<lb/>It recrystallized in MeOH and acquired the colorless
                                    crystal|crystallization 13 (g [ 28.0 ], yield 98%).
                                </p>
                                <p xml:id="_bb67360619" n="0091">Compound 14:<lb/>The compound 13(28.2g, 71.7mmol),
                                    Et3N(20mL, 143.4mmol), the chlorinated trityl (25.98 g, 93.2mmol), and DMAP (0.13 g,
                                    1.07mmol) which use DMF (300 mL) as a solvent were added to the round bottom flask.
                                    <lb/>This mixture was stirred at 50 degreeC under N2 for 30 hours, water (1000 mL)
                                    was inject|poured succeedingly, and it extracted by EtOAc (5x200 mL).<lb/>The mixed
                                    extract was wash|cleaned by water and a brine, and it dried on MgSO4 after that.
                                    <lb/>After removing a solvent under reduced pressure, the residue was
                                    refine|purified using the SiO2 chromatography (The eluting solvent :CH2Cl2, Et2O and
                                    MeOH) and the pale yellow solid substance 14 was obtained (31.9 g, yield 70%).
                                </p>
                                <p xml:id="_bb67360624" n="0092">Compound 15:<lb/>The compound 14 (g [ 20.0 ], 31.4mmol)
                                    and NaH(They are 60 %, 6.3 g, and 157.2mmol in a mineral oil.) which use anhydrous
                                    THF (600 mL) as a solvent were added to the round bottom flask.<lb/>This mixture was
                                    recirculate|refluxed for 30 minutes under N2, and the allyl bromide (27 mL, 314mmol)
                                    was added succeedingly.<lb/>After recirculate|refluxing for 60 hours, NaH (3
                                    equivalent) and an allyl bromide (4 equivalent) were added.<lb/>It
                                    recirculate|refluxed succeedingly for further 50 hours, and water (20 mL) was
                                    inject|poured slowly, and succeedingly, 1%, HCl was added until the water phase
                                    became neutral.<lb/>After that, ether extracted this mixture (3x100 mL), and it
                                    wash|cleaned the mixed extract by water (100 mL) and a brine (2x100 mL).<lb/>This
                                    ether solution is dried on anhydrous Na2SO4,<lb/>The solvent was removed,<lb/>Then,
                                    the residue was refine|purified using the SiO2 chromatography (Eluting solvent:
                                    Hexane, EtOAc/hexane, 1:8) and the pale yellow glass-like compound 15 was obtained
                                    (22.76 g, yield 96%).
                                </p>
                                <p xml:id="_bb67360633" n="0093">Compound 16:<lb/>The compound 15 (g [ 3.34 ], 4.4mmol)
                                    and methanol (100 mL) which use CH2Cl2(200mL) as a solvent were added to the three
                                    neck round bottom flask.<lb/>It let the cooled solution (-78 degreeC) ozone pass,
                                    and it foamed until blue came to have maintained.<lb/>The oxygen flow removed an
                                    excessive quantity of ozone.<lb/>This mixture was left still in the dry ice acetone
                                    bath for 1 hour.<lb/>A methyl sulfide (2.4 mL) is added,<lb/>And this mixture is
                                    processed in 15 minutes by NaBH4(1.21g, 32mmol) which uses a 5% NaOH
                                    aqueous-solution (10 mL)/methanol (10 mL) as a solvent,<lb/>It warmed to room
                                    temperature.<lb/>This mixture was wash|cleaned by the brine (3x50 mL), and the mixed
                                    brine washing|cleaning liquid was extracted by CH2Cl2 (2x50 mL).<lb/>This organic
                                    phase was dried on MgSO4.<lb/>The oily compound 16 was isolated after SiO2
                                    chromatography (Inside MeOH of CH2Cl2 (5 %) ) (3.30 g, yield 95%).
                                </p>
                                <p xml:id="_bb67360644" n="0094">Compound 17:<lb/>The compound 16 (g [ 1.17 ], 1.55mmol)
                                    which uses anhydrous THF (30 mL) as a solvent under N2 in an ice bath is added to a
                                    round bottom flask,<lb/>The 9-BBN/THF solution (0.5M, 10.2mL, 5.51mmol) was added
                                    succeedingly.<lb/>This mixture was stirred at room temperature for 12 hours.
                                    <lb/>
                                    NaOH aqueous solution (20 %) (2 mL) and a hydrogen-peroxide solution (30 %) (2 mL)
                                    were added one by one.<lb/>After recirculate|refluxing this mixture for 1 hour, the
                                    brine (60 mL) was added and it extracted by EtOAc (4x30 mL).<lb/>The mixed extract
                                    was dried on anhydrous Na2SO4.<lb/>The product was obtained as a colorless oily
                                    substance after SiO2 chromatography (5-%MeOH in CH2Cl2) (1.01 g, yield 80%).
                                </p>
                                <p xml:id="_bb67360652" n="0095">Compound 18:<lb/>The compound 16 (g [ 3.30 ], 4.29mmol)
                                    and NEt3(2.09mL, 15.01mmol) which use CH2Cl2(150mL) as a solvent were added to the
                                    round bottom flask.<lb/>This mixture was set|placed under N2 in an ice bath, and the
                                    chlorinated mesyl (1.01 mL, 14.16mmol) was added succeedingly.<lb/>Water (30 mL) and
                                    a brine (200 mL) were added 30 minutes afterward.<lb/>The CH2Cl2 phase was
                                    wash|cleaned by the brine (2x50 mL), and it dried on anhydrous Na2SO4.<lb/>The mixed
                                    aqueous|water-based mixture was extracted by EtOAc (3x100 mL).<lb/>The mixed extract
                                    was wash|cleaned by the brine and it dried on anhydrous Na2SO4.<lb/>The desired
                                    product was isolated as a pale yellow oily substance after the SiO2 chromatography
                                    (EtOAc/hexane, 1:1) (3.35 g, yield 78%).
                                </p>
                                <p xml:id="_bb67360660" n="0096">Compound 19:<lb/>The compound 17 (g [ 1.01 ], 1.25mmol)
                                    and NEt3(0.608mL, 4.36mmol) which use CH2Cl2(50mL) as a solvent were added to the
                                    round bottom flask.<lb/>This mixture was set|placed under N2 in an ice bath, and the
                                    chlorinated mesyl (0.318 mL, 4.11mmol) was added succeedingly.<lb/>The brine (80 mL)
                                    was added for water (10 mL) after that 30 minutes afterward.<lb/>The CH2Cl2 phase
                                    was wash|cleaned by the brine (2x20 mL), and it dried on anhydrous Na2SO4.<lb/>The
                                    mixed aqueous|water-based mixture was extracted by EtOAc (3x40 mL).<lb/>The mixed
                                    extract was wash|cleaned by the brine and it dried on anhydrous Na2SO4.<lb/>The
                                    desired product was isolated as a pale yellow oily substance after the SiO2
                                    chromatography (EtOAc/hexane, 1:1) (1.07 g, yield 82%).
                                </p>
                                <p xml:id="_bb67360668" n="0097">Compound 20:<lb/>The compound 18 (g [ 1.50 ], 1.50mmol)
                                    and NaN3(0.976g, 15mmol) which use anhydrous DMSO (20 mL) as a solvent were added to
                                    the round bottom flask.<lb/>It heated at 80 degreeC, and this mixture was stirred
                                    overnight and diluted with the bottom of N2 with water (100 mL) after that.<lb/>The
                                    obtained aqueous|water-based mixture was extracted by EtOAc (3x50 mL), and the mixed
                                    extract was wash|cleaned by the brine, and it dried on anhydrous Na2SO4.<lb/>The
                                    desired product was isolated as a transparent glass-like thing after the SiO2
                                    chromatography (EtOAc/hexane, 1:5) (0.83 g, yield 66%).
                                </p>
                                <p xml:id="_bb67360673" n="0098">Compound 22:<lb/>The compound 20 (mg<lb/>830<lb/>,
                                    0.984mmol), CH2Cl2(30mL), and p-toluenesulfonic acid (9.35 mg, 0.0492mmol) which use
                                    MeOH (30 mL) as a solvent were added to the round bottom flask.<lb/>This solution
                                    was stirred at room temperature for 2.5 hours, and NaHCO3 saturated aqueous solution
                                    (10 mL) was inject|poured after that.<lb/>The brine (30 mL) was added and the
                                    mixture was extracted by EtOAc (4x20 mL).<lb/>The mixed extract was dried on
                                    anhydrous Na2SO4.<lb/>The desired product was isolated as a pale yellow oily
                                    substance after the SiO2 chromatography (EtOAc/hexane, 1:2) (0.564 g, yield 95%).
                                </p>
                                <p xml:id="_bb67360681" n="0099">Compound 23:<lb/>The compound 19 (g [ 1.07 ],
                                    1.025mmol) and NaN3(0.666g, 10.25mmol) were added to the round bottom flask, and
                                    anhydrous DMSO (15 mL) was inject|poured into it after that.<lb/>This mixture was
                                    heated at a maximum of 80 degreeC under N2 overnight.<lb/>This mixture was extracted
                                    by EtOAc after H2O (100 mL) addition (4x40 mL), and the mixed extract was dried on
                                    anhydrous Na2SO4.<lb/>The solvent was removed,<lb/>Then, a residue is melt|dissolved
                                    in MeOH (15 mL) and CH2Cl2(15mL),<lb/>P-toluenesulfonic acid (9.75 mg, 0.051mmol) of
                                    the catalyst amount was added succeedingly.<lb/>This solution was stirred at room
                                    temperature for 2.5 hours, and the saturated NaHCO3 solution (15 mL) was added after
                                    that.<lb/>After adding a brine (60 mL), this mixture was extracted by EtOAc (5x30
                                    mL).<lb/>The brine (150 mL) was added to the mixed extract, and it dried on
                                    anhydrous Na2SO4.<lb/>The desired product was obtained as a yellowish oily substance
                                    after the SiO2 chromatography (EtOAc/hexane, 1:2) (0.617 g, two steps of yield 94%).
                                </p>
                                <p xml:id="_bb67360692" n="0100">Compound 24:<lb/>The compound 22 (g [ 0.564 ],
                                    0.938mmol) and NEt3(0.20mL, 1.40mmol) which use CH2Cl2(30mL) as a solvent were added
                                    to the round bottom flask.<lb/>This mixture was put into the ice bath under N2, and
                                    the chlorinated mesyl (0.087 mL, 1.13mL) was added succeedingly.<lb/>Water (20 mL)
                                    and a brine (100 mL) were added 30 minutes afterward.<lb/>The CH2Cl2 phase was
                                    wash|cleaned by the brine (2x20 mL), and it dried on anhydrous Na2SO4.<lb/>The mixed
                                    aqueous|water-based mixture was extracted by EtOAc (3x30 mL).<lb/>The mixed extract
                                    was wash|cleaned by the brine and it dried on anhydrous Na2SO4.<lb/>The desired
                                    product was obtained as a yellowish oily substance after the SiO2 chromatography
                                    (EtOAc/hexane, 1:2) (0.634 g, yield 99%).
                                </p>
                                <p xml:id="_bb67360700" n="0101">Compound 25:<lb/>The compound 23 (0.617 g-0.96mmol) and
                                    NEt3(0.20mL, 1.44mmol) were added to the round bottom flask in CH2Cl2(30mL).
                                    <lb/>
                                    This mixture was put into the ice bath under N2, and the chlorinated mesyl (0.089
                                    mL, 1.15mmol) was added succeedingly.<lb/>Water (20 mL) and a brine (120 mL) were
                                    added 30 minutes afterward.<lb/>The CH2Cl2 phase was wash|cleaned by the brine (2x20
                                    mL), and it dried on anhydrous Na2SO4.<lb/>The mixed aqueous|water-based mixture was
                                    extracted by EtOAc (3x30 mL).<lb/>The mixed extract was wash|cleaned by the brine
                                    and it dried on anhydrous Na2SO4.<lb/>After removing a solvent, the desired product
                                    was obtained as an oily substance which pale yellow cut (0.676 g, yield 97%).
                                </p>
                                <p xml:id="_bb67360708" n="0102">Compound 26:<lb/>The compound 24 (g [ 0.634 ],
                                    0.936mmol) and N-benzyl methylamine (2 mL) were added to a 50 mL round bottom flask.
                                    <lb/>This mixture was heated at 80 degreeC under N2 overnight.<lb/>Excess N-benzyl
                                    methylamine was removed under reduced pressure, and the residue was covered over the
                                    SiO2 chromatography (EtOAc/hexane, 1:2).<lb/>The desired product was isolated as a
                                    pale yellow oily substance (0.6236 g, yield 95%).
                                </p>
                                <p xml:id="_bb67360713" n="0103">Compound 27:<lb/>The compound 25 (g [ 0.676 ],
                                    0.937mmol) and N-benzyl methylamine (2 mL) were added to a 50 mL round bottom flask.
                                    <lb/>This mixture was heated at 80 degreeC overnight [ bottom of N2 ].<lb/>Excess
                                    N-benzyl methylamine was removed under reduced pressure, and the residue was covered
                                    over the SiO2 chromatography (EtOAc/hexane, 1:2).<lb/>The desired product was
                                    isolated as a pale yellow oily substance (0.672 g, yield 96%).
                                </p>
                                <p xml:id="_bb67360718" n="0104">Compound 1:<lb/>The compound 26 (g [ 0.684 ],
                                    0.971mmol) and LiAlH4(113.7mg, 3.0mmol) which use anhydrous THF (30 mL) as a solvent
                                    were added to the round bottom flask under N2.<lb/>This mixture was stirred at room
                                    temperature for 12 hours, and the Na2SO4*10H2O powder (10g) was added slowly after
                                    that.<lb/>After gray lose|disappeared, this mixture was filtered through cerite and
                                    it wash|cleaned by anhydrous THF.<lb/>The product was obtained as a colorless
                                    glass-like thing (0.581 g, yield 95%).
                                </p>
                                <p xml:id="_bb67360723" n="0105">The HCl salt of the compound 1<lb/>The compound 1 was
                                    melt|dissolved in CH2Cl2 of the minimum quantity, and the HCl excessive quantity
                                    which uses ether as a solvent was added.<lb/>A solvent and an excessive quantity of
                                    HCl(s) were removed under reduced pressure, and the amorphous|non-crystalline white
                                    powder was obtained.
                                </p>
                                <p xml:id="_bb67360726" n="0106">Compound 2:<lb/>The compound 27 (g [ 0.82 ], 1.10mmol)
                                    and LiAlH4(125mg, 3.30mmol) which use anhydrous THF (150 mL) as a solvent were added
                                    to the round bottom flask under N2.<lb/>This mixture was stirred at room temperature
                                    for 12 hours, and the Na2SO4*10H2O powder (10g) was added slowly after that.
                                    <lb/>
                                    After gray lose|disappeared, this mixture was filtered through the cotton plug, and
                                    it wash|cleaned by anhydrous THF.<lb/>THF was removed under reduced pressure and the
                                    residue was melt|dissolved in CH2Cl2(50mL).<lb/>The desired white flint-like product
                                    was obtained after filtration (0.73 g, yield 99%).
                                </p>
                                <p xml:id="_bb67360732" n="0107">The HCl salt of the compound 2<lb/>The compound 2 was
                                    melt|dissolved in CH2Cl2 of the minimum quantity, and the HCl excessive quantity
                                    which uses ether as a solvent was added.<lb/>A solvent and an excessive quantity of
                                    HCl(s) were removed, and the amorphous|non-crystalline white powder was obtained.
                                </p>
                                <p xml:id="_bb67360735" n="0108">Compound 4:<lb/>Suspension became transparent when
                                    suspension of the compound 1 (mg [ 79.1 ], 0.126mmol) which uses methanol and
                                    chloroform as a solvent, and amino imino methanesulfonic acid (50.15 mg, 0.404mmol)
                                    was stirred at room temperature for 24 hours.<lb/>The ether solution of HCl (1 M,
                                    1mL) was added, and the N2 flow removed the solvent succeedingly.<lb/>The residue
                                    was melt|dissolved in H2O (5 mL) and the 20% NaOH aqueous-solution (0.5 mL) was
                                    added after that.<lb/>The obtained cloudy mixture was extracted by CH2Cl2 (4x5 mL).
                                    <lb/>The mixed extract was dried on anhydrous Na2SO4.<lb/>The solvent was removed
                                    and the desired product was obtained as a white powder (90 mg, yield 95%).
                                </p>
                                <p xml:id="_bb67360742" n="0109">The HCl salt of the compound 4<lb/>The compound 4 was
                                    melt|dissolved in CH2Cl2 of minimum amount, and MeOH, and the HCl excessive quantity
                                    which uses ether as a solvent succeedingly was added.<lb/>The N2 flow removed the
                                    solvent and it set|placed the residue on the high pressure reduction state
                                    overnight.<lb/>The desired product was obtained as an amorphous|non-crystalline
                                    white powder.
                                </p>
                                <p xml:id="_bb67360746" n="0110">Compound 5:<lb/>Suspension of the compound 2 (mg
                                    <lb/>
                                    113<lb/>, 0.169mmol) which uses methanol and chloroform as a solvent, and amino
                                    imino methanesulfonic acid (67.1 mg, 0.541mmol) was stirred at room temperature for
                                    24 hours.<lb/>HCl (1 M, 1mL) which uses ether as a solvent was added, and the N2
                                    flow removed the solvent succeedingly.<lb/>The residue was set|placed on the high
                                    pressure reduction state overnight, and it melt|dissolved in H2O (5 mL), and added
                                    the 20% NaOH aqueous-solution (1.0 mL) after that.<lb/>The obtained mixture was
                                    extracted by CH2Cl2 (5x5 mL).<lb/>The mixed extract was dried on anhydrous Na2SO4.
                                    <lb/>The solvent was removed and the desired product was obtained as a white solid
                                    substance (90 mg, yield 95%).
                                </p>
                                <p xml:id="_bb67360755" n="0111">The HCl salt of the compound 5<lb/>The compound 5 was
                                    melt|dissolved in CH2Cl2 of minimum amount, and MeOH, and the HCl excessive quantity
                                    which uses ether as a solvent succeedingly was added.<lb/>The N2 flow removed a
                                    solvent and excess HCl, and it set|placed the residue on the high pressure reduction
                                    state overnight.<lb/>The desired product was obtained as an
                                    amorphous|non-crystalline white powder.
                                </p>
                                <p xml:id="_bb67360759" n="0112">Example 2<lb/>Compound 28:<lb/>The compound 19 (g [
                                    0.641 ], 0.614mmol) which uses anhydrous DMSO (5 mL) as a solvent, and suspension of
                                    KCN (0.40 g, 6.14mmol) were stirred under N2 at 80 degreeC overnight,<lb/>Then, H2O
                                    (50 mL) was added.<lb/>Aqueous|water-based mixture was extracted by EtOAc (4x20 mL).
                                    <lb/>The mixed extract was wash|cleaned once by the brine, and it dried on anhydrous
                                    Na2SO4, and concentrated under reduced pressure.<lb/>The residue was melt|dissolved
                                    in CH2Cl2(3mL) and p-toluenesulfonic acid (5.84 mg, 0.03mmol) of MeOH (3 mL) and a
                                    catalyst amount was added.<lb/>This solution was stirred at room temperature for 3
                                    hours, and the NaHCO3 saturated solution (10 mL) was inject|poured after that.
                                    <lb/>
                                    After adding a brine (60 mL), the mixture was extracted by EtOAc (4x30 mL).<lb/>The
                                    mixed extract was wash|cleaned once by the brine, and it dried and concentrated on
                                    anhydrous Na2SO4.<lb/>The residue obtained the desired product after column
                                    chromatography (A silica gel, EtOAc/hexane, 2:1) as an oily substance which pale
                                    yellow cut (0.342 g, yield 92%).
                                </p>
                                <p xml:id="_bb67360770" n="0113">Compound 29:<lb/>NEt3(119.5(micro|micron|mu)L,
                                    0.857mmol) is added to compound 28 (0.34 g, 0.57mmol) solution which uses anhydrous
                                    CH2Cl2(15mL) as a solvent under 0 degreeCN2,<lb/>Then, the chlorinated mesyl (53.1
                                    microliters, 0.686mmol) was added.<lb/>The mixture was stirred at 0 degreeC for 30
                                    minute(s), and H2O (6 mL) was added after that.<lb/>After inject|pouring a brine (60
                                    mL), aqueous|water-based mixture was extracted by EtOAc (4x20 mL).<lb/>The mixed
                                    extract was wash|cleaned once by the brine, and it dried and concentrated on
                                    anhydrous Na2SO4.<lb/>N-benzyl methylamine (0.5 mL) was added to the residue, and
                                    the mixture was stirred under 80 degreeCN2 overnight.<lb/>Excess N-benzyl
                                    methylamine is removed under reduced pressure,<lb/>The residue was covered over
                                    column chromatography and the product was obtained as a pale yellow oily substance
                                    after (It is EtOAc to a silica gel, EtOAc/hexane, 2:1, and the next.) (0.35 g, yield
                                    88%).
                                </p>
                                <p xml:id="_bb67360779" n="0114">Compound 3:<lb/>Compound 29 (0.074 g, 0.106mmol)
                                    solution which uses anhydrous THF (10 mL) as a solvent was dripped at the mixture of
                                    AlCl3(0.1414g, 1.06mmol) and LiAlH4(0.041g, 1.06mmol) which uses anhydrous THF (10
                                    mL) as a solvent.<lb/>This suspension was stirred for 24 hours and the 20% NaOH
                                    aqueous-solution (2 mL) was added at ice bath temperature after that.<lb/>Anhydrous
                                    Na2SO4 was added to this aqueous slurry.<lb/>The solution was filtered and
                                    precipitation was wash|cleaned twice by THF.<lb/>After removing a solvent, the
                                    residue was covered over column chromatography and (It is MeOH/CH2Cl2/NH3*H2O, and
                                    4:4:1 to a silica gel, MeOH/CH2Cl2, 1:1, and the next.) and a desired product were
                                    obtained as a transparent oily substance (0.038 g, yield 50%).
                                </p>
                                <p xml:id="_bb67360785" n="0115">Example 3<lb/>Compound 30:<lb/>The cholic acid (3.0 g,
                                    7.3mmol) was melt|dissolved in CH2Cl2(50mL) and methanol (5 mL).<lb/>A
                                    dicyclohexylcarbodiimide (DCC) (1.8 g, 8.8mmol) is added,<lb/>N-hydroxysuccinimide
                                    (- 100 mg) and the benzyl methylamine (1.1 g, 8.8mmol) were added after that.
                                    <lb/>
                                    This mixture was stirred for 2 hours and filtered after that.<lb/>The filtrate was
                                    concentrated, and it applied to the chromatography, and obtained (3-%MeOH which uses
                                    SiO2 and CH2Cl2 as a solvent) and the white solid substance 3.0g (yield 81%).
                                </p>
                                <p xml:id="_bb67360792" n="0116">Compound 31:<lb/>The compound 30 (g [ 2.4 ], 4.7mmol)
                                    was added to LiAlH4(0.18g, 4.7mmol) suspension which uses THF (50 mL) as a solvent.
                                    <lb/>It recirculate|refluxed for 24 hours and cooled this mixture at 0 degreeC after
                                    that.<lb/>Na2SO4 aqueous solution was carefully added until the gray of the mixture
                                    disappeared.<lb/>The obtained salt was filtered, the filtrate was concentrated under
                                    reduced pressure, and the white solid substance 2.1g (88 %) was obtained.<lb/>It was
                                    authenticated that this product has sufficient purity for future reaction.
                                </p>
                                <p xml:id="_bb67360798" n="0117">Compound 32:<lb/>The compound 31 (g [ 0.36 ], 0.72mmol)
                                    is melt|dissolved in CH2Cl2(15mL),<lb/>And Boc-glycine (0.51 g, 2.89mmol), DCC (0.67
                                    g, 3.24mmol), and a dimethylamino pyridine (DMAP) (- 100 mg) were added.<lb/>Under
                                    N2, this mixture was stirred for 4 hours and filtered after that.<lb/>0.47 g of
                                    products of the shape of transparent glass were obtained after concentration and
                                    chromatography (5-%MeOH which uses SiO2 and CH2Cl2 as a solvent) (68 %).
                                </p>
                                <p xml:id="_bb67360803" n="0118">Compound 33:<lb/>The compound 31 (g [ 0.39 ], 0.79mmol)
                                    is melt|dissolved in CH2Cl2(15mL),<lb/>And the Boc-beta-alanine (0.60 g, 3.17mmol),
                                    DCC (0.73 g, 3.56mmol), and a dimethylamino pyridine (DMAP) (- 100 mg) were added.
                                    <lb/>Under N2, this mixture was stirred for 6 hours and filtered after that.
                                    <lb/>
                                    0.58 g of products of the shape of transparent glass were obtained after
                                    concentration and chromatography (5-%MeOH which uses SiO2 and CH2Cl2 as a solvent)
                                    (72 %).
                                </p>
                                <p xml:id="_bb67360808" n="0119">Compound 6:<lb/>The compound 32 (g [ 0.15 ], 0.15mmol)
                                    was stirred for 40 minutes with the excessive quantity of 4N HCl in a dioxane.
                                    <lb/>
                                    When a dioxane and HCl were removed under reduced pressure, 0.12 g of products of
                                    the shape of transparent glass remained (- 100 %).
                                </p>
                                <p xml:id="_bb67360811" n="0120">Compound 7:<lb/>The compound 33 (g [ 0.20 ], 0.20mmol)
                                    was stirred for 40 minutes with the excessive quantity of 4N HCl in a dioxane.
                                    <lb/>
                                    When a dioxane and HCl were removed under reduced pressure, 0.12 g of products of
                                    the shape of transparent glass remained (- 100 %).
                                </p>
                                <p xml:id="_bb67360814" n="0121">Example 4<lb/>Compound 34:<lb/>Diisopropyl azodi
                                    carboxylate (DIAD)(1.20mL, 6.08mmol) is added to the triphenylphosphine (1.60 g,
                                    6.08mmol) which uses THF (100 mL) as a solvent at 0 degreeC,<lb/>And it stirs for 30
                                    minutes,<lb/>The yellow solution became paste-form in-between|in-the-meantime.
                                    <lb/>
                                    It melt|dissolved in THF (50 mL) and added the compound 14 (g [ 2.58 ], 4.06mmol)
                                    and p-nitrobenzoic acid (0.81 g, 4.87mmol) to the paste.<lb/>The obtained mixture
                                    was stirred at ambient temperature overnight.<lb/>Water (100 mL) was added, and by
                                    adding a NaHCO3 solution, this mixture was made slightly basic and extracted by
                                    EtOAc after that (3x50 mL).<lb/>The mixed extract was wash|cleaned once by the
                                    brine, and it dried on anhydrous Na2SO4.<lb/>The desired product was obtained as a
                                    white powder after SiO2 chromatography (Et2O / hexane, 1:2) (2.72 g, yield 85%).
                                    <lb/>Nitrobenzoic acid (2.75 g, 3.5mmol) was melt|dissolved in CH2Cl2(40mL), and
                                    MeOH (20 mL) and a 20% NaOH aqueous-solution (5 mL) were added.<lb/>The mixture was
                                    heated at a maximum of 60 degreeC for 24 hours.<lb/>Water (100 mL) was inject|poured
                                    and it extracted by EtOAc.<lb/>The mixed extract was wash|cleaned by the brine and
                                    it dried on anhydrous Na2SO4.<lb/>The desired product of the white solid substance
                                    was obtained after SiO2 chromatography (3-%MeOH which uses eluting solvent CH2Cl2 as
                                    a solvent) (1.89 g, yield 85%).
                                </p>
                                <p xml:id="_bb67360829" n="0122">Compound 35:<lb/>Compound 34(2.0g, 3.14mmol), NaH (They
                                    are 60 %, 3.8 g, and 31.4mmol in a mineral oil.) and THF (150 mL) were added to the
                                    round bottom flask.<lb/>This suspension was recirculate|refluxed for 2 hours and the
                                    allyl bromide (2.72 mL, 31.4mmol) was added after that.<lb/>After
                                    recirculate|refluxing for 28 hours, 10 equivalent NaH and an allyl bromide were
                                    added.<lb/>72 hours after and also 10 equivalent NaH, and an allyl bromide were
                                    added.<lb/>The result of TLC showed that a starting material and an intermediate
                                    body hardly existed 115 hours afterward.<lb/>Water (100 mL) was carefully added to
                                    this suspension, and it extracted by EtOAc succeedingly (5x50 mL).<lb/>The mixed
                                    extract was wash|cleaned by the brine and it dried on anhydrous Na2SO4.<lb/>The
                                    desired product of the shape of yellowish glass was obtained after the SiO2
                                    chromatography (5-%EtOAc / hexane) (1.81 g, yield 79%).
                                </p>
                                <p xml:id="_bb67360838" n="0123">Compound 36:<lb/>Bubble injection|pouring of the ozone
                                    was carried out until the solution changed to the solution which put 35 (0.551 g,
                                    0.729 mmol) into CH2Cl2(40mL) and MeOH (20 mL) at -78 degreeC at deep blue.<lb/>An
                                    excessive quantity of ozone blew away with oxygen.<lb/>NaBH4(0.22g, 5.80mmol) which
                                    added, and put the methyl sulfide (1 mL) into 5% of NaOH solution and methanol
                                    continuously was added.<lb/>The obtained liquid mixture was stirred at room
                                    temperature overnight, and it wash|cleaned with salt water.<lb/>Next, the salt water
                                    was extracted by EtOAc (3x20 mL).<lb/>The set extract was dried on Na2SO4.<lb/>After
                                    the target product (0.36 g, yield 65%) performed the SiO2 chromatography (5% of
                                    MeOH/CH2Cl2), it was obtained as a colorless glassy material.
                                </p>
                                <p xml:id="_bb67360846" n="0124">Compound 37:<lb/>NEt3(0.23mL, 1.66mmol) is added to the
                                    dry CH2Cl2(30mL) solution of 36 (0.364 g, 0.47 mmol) under N2 airflow at 0 degreeC,
                                    <lb/>Then, the mesyl chloride (0.12 mL, 1.56 mmol) was introduce|transduced.
                                    <lb/>
                                    This liquid mixture was stirred for 10 minutes, and after adding H2O (10 mL) and
                                    stopping|fastening that reaction, it extracted by EtOAc (3x30 mL).<lb/>The set
                                    extract was wash|cleaned with salt water and it dried on anhydrous Na2SO4.<lb/>The
                                    SiO2 chromatography (EtOAc / hexane 1:1) was performed, and the target product
                                    (0.411 g, yield 86%) was obtained as a white glassy material.
                                </p>
                                <p xml:id="_bb67360852" n="0125">Compound 38:<lb/>Suspension which put 37 (0.227 g,
                                    0.227 mmol) and NaN3(0.147g, 2.27mmol) in dry DMSO (5 mL) is stirred at 80 degreeC
                                    overnight,<lb/>After diluting with H2O (50 mL), it extracted by EtOAc (3x20 mL).
                                    <lb/>The extract was wash|cleaned with salt water and it dried on anhydrous Na2SO4.
                                    <lb/>The SiO2 chromatography (EtOAc / hexane 1:8) was performed, and the target
                                    product (0.153 g, yield 80%) was obtained as yellow oil.
                                </p>
                                <p xml:id="_bb67360857" n="0126">Compound 39:<lb/>P-toluenesulfonic acid (1.72 mg) is
                                    added to the solution which put 38 (0.153 g, 0.18 mmol) into CH2Cl2(5mL) and MeOH (5
                                    mL),<lb/>The liquid mixture was stirred for 2.5 hours.<lb/>After
                                    introduce|transducing the saturated NaHCO3 solution (5 mL), salt water (30 mL) was
                                    inject|poured.<lb/>After extracting the aqueous|water-based liquid mixture using
                                    EtOAc and wash|cleaning the set extract with salt water, it dried on Na2SO4.<lb/>The
                                    SiO2 chromatography (EtOAc / hexane 1:3) was performed, and the target product (0.10
                                    g, yield 92%) was obtained as pale yellow oil.
                                </p>
                                <p xml:id="_bb67360863" n="0127">Compound 40:<lb/>NEt3(34.8(micro|micron|mu)L, 0.25mmol)
                                    is added to the CH2Cl2(8mL) solution of 39 (0.10 g, 0.166 mmol) under N2 airflow at
                                    0 degreeC,<lb/>Then, the mesyl chloride (15.5 microliters, 0.199 mmol) was
                                    introduce|transduced.<lb/>This liquid mixture was stirred for 15 minutes.<lb/>H2O (3
                                    mL) and salt water (20 mL) were added, and it extracted by EtOAc (4x10 mL).<lb/>The
                                    set extract was once wash|cleaned with salt water, and it dried on Na2SO4.<lb/>After
                                    removing the solvent, the residue was mixed with N-benzyl methylamine (0.5 mL), and
                                    was heated at 80 degreeC overnight [ bottom of N2 airflow ].<lb/>Excess N-benzyl
                                    methylamine is removed under reduced pressure,<lb/>The product (0.109 g, yield 93%)
                                    was obtained as yellow oil by covering the residue over a SiO2 chromatography (EtOAc
                                    / hexane 1:4).
                                </p>
                                <p xml:id="_bb67360872" n="0128">Compound 8:<lb/>Suspension which put 40 (0.109 g, 0.155
                                    mmol) and LiAlH4(23.5mg, 0.62mmol) in THF (20 mL) was stirred under N2 airflow
                                    overnight.<lb/>Na2SO4*10H2O was added carefully, and it stirred until that gray is
                                    lose|eliminated maintained.<lb/>Anhydrous Na2SO4 was added, the white deposit was
                                    filtered and it rinsed by dry THF.<lb/>After removing the solvent, it melt|dissolved
                                    in CH2Cl2 of minimum amount and filtered the residue.<lb/>A removal of the solvent
                                    obtained the target product (0.091 g, yield 94%) as colorless oil.
                                </p>
                                <p xml:id="_bb67360878" n="0129">Compound 9:<lb/>NaH(They are 60 % and 5.60 mmol in
                                    0.224 g and a mineral oil.) and the 1-bromo- octane (0.48 mL, 2.80 mmol) were added
                                    to the dry DMF (4 mL) solution of 23 (0.18 g, 0.28 mmol).<lb/>This suspension was
                                    stirred at 65 degreeC under N2 airflow overnight, H2O (60 mL) was
                                    introduce|transduced continuously, and ether (4x20 mL) extracted.<lb/>The set
                                    extract was wash|cleaned with salt water and it dried on Na2SO4.<lb/>The SiO2
                                    chromatography (Hexane and hexane containing 5% of EtOAc) was performed and the
                                    target product (0.169 g, yield 80%) was obtained as light yellowish oil.<lb/>Tri
                                    azide (0.169 g, 0.224 mmol) and LiAlH4(0.025g, 0.67mmol) are suspended in anhydrous
                                    THF (10 mL),<lb/>Under N2 airflow, after stirring at room temperature overnight,
                                    Na2SO4 hydrate was added carefully.<lb/>Anhydrous Na2SO4 was added and stirred after
                                    gray was lose|eliminated.<lb/>The white deposit|precipitate was filtered and removed
                                    and it wash|cleaned by THF.<lb/>After removing the solvent, the residue was
                                    melt|dissolved in 1-M hydrochloric acid, and the aqueous solution was extracted once
                                    using ether (5 mL).<lb/>Then, by adding 20% of aqueous|water-based NaOH solution,
                                    the aqueous solution was made basic and extracted by Et2O (4x5 mL).<lb/>The set
                                    extract was wash|cleaned, and it dried and concentrated.<lb/>And the target product
                                    (0.091 g, yield 60%) was obtained as colorless oil, having covered the residue over
                                    the SiO2 chromatography (MeOH/CH2Cl2 (1:1) They are MeOH/CH2Cl2 / NH3*H2O (4:4:1)
                                    continuously.).
                                </p>
                                <p xml:id="_bb67360891" n="0130">Compound 10:<lb/>Suspension which put 23 (0.126 g,
                                    0.196 mmol) and LiAlH4(0.037g, 0.98mmol) in THF (40 mL) is stirred at room
                                    temperature under N2 airflow overnight,<lb/>Then, Na2SO4*10H2O was added carefully.
                                    <lb/>It stirred until it added anhydrous Na2SO4 and the organic layer became
                                    transparent, after the gray of the suspension lose|disappeared.<lb/>After filtering
                                    and removing the white deposit|precipitate, it wash|cleaned twice using THF.<lb/>THF
                                    is removed under reduced pressure,<lb/>The target product (0.066 g, yield 60%) was
                                    obtained as colorless oil, having covered the residue over the SiO2 chromatography
                                    (MeOH/CH2Cl2/NH3*H2O (4:4:1)).
                                </p>
                                <p xml:id="_bb67360898" n="0131">Example 5<lb/>Compound 43:<lb/>The compound 41 was
                                    prepared in accordance with the method reported by D. H. R. Barton, J. Wozniak, S.
                                    Z. Zard, A Short And Efficient Degredation of The Bile Acid Side Chain. Some Novel
                                    Reactions of Sulphines And A-ketoesters, Tetrahedron 1989, vol.45, 3741-3754.<lb/>41
                                    (1.00 g, 2.10 mmol), ethylene glycol (3.52 mL, 63 mmol), and the mixture of
                                    p-TsOH(20mg, 0.105mmol) were recirculate|refluxed in benzene under N2 airflow for 16
                                    hours.<lb/>The Dean- Stark (Dean-Stark) water|moisture-content trap removed the
                                    water formed between this reaction.<lb/>The NaHCO3 solution (50 mL) wash|cleaned the
                                    cooled mixture, and it extracted using Et2O(50mL, 2*30mL).<lb/>The set extract was
                                    wash|cleaned with salt water and it dried on anhydrous Na2SO4.<lb/>A removal of the
                                    solvent obtained the product (1.09 g, 100 %) as a white glassy material.<lb/>This
                                    triacetate (1.09 g, 2.10 mmol) was melt|dissolved in MeOH (50 mL).<lb/>NaOH(0.84 g,
                                    21 mmol) was added to the solution.<lb/>This suspension was continued and it
                                    recirculate|refluxed under N2 airflow for 24 hours.<lb/>Next, MeOH is
                                    pressure-reduced and removed,<lb/>After melt|dissolving the residue in Et2O (100 mL)
                                    and wash|cleaning with H20 and salt water, it dried on anhydrous Na2SO4.<lb/>A
                                    removal of the solvent obtained the target product (0.80 g, yield 96%) as white
                                    solid.
                                </p>
                                <p xml:id="_bb67360912" n="0132">Compound 44:<lb/>NaH(They are 60 %, 0.81 g, and 20.3
                                    mmol in a mineral oil.) was added after adding 43 (0.80 g, 2.03 mmol) and dry THF
                                    (100 mL) to the round bottom flask.<lb/>This suspension was recirculate|refluxed for
                                    30 minutes under N2 airflow, and allyl|allele bromide (1.75 mL, 20.3 mmol) was
                                    added.<lb/>After recirculate|refluxing for 48 hours, 10 equivalent NaH and
                                    allyl|allele bromide were added.<lb/>After 48 more hour had passed, TLC showed that
                                    no intermediate bodies were formed.<lb/>The cooling water (50 mL) was added to the
                                    cooling suspension.<lb/>The obtained liquid mixture was extracted using Et2O(60mL,
                                    2*30mL).<lb/>The set extract was wash|cleaned with salt water and it dried on
                                    anhydrous Na2SO4.<lb/>When SiO2 column chromatography (inside of hexane 6% of EtOAc)
                                    was performed, the product (0.94 g, yield 90%) made into the objective was obtained
                                    as light yellow oil.
                                </p>
                                <p xml:id="_bb67360921" n="0133">Compound 45:<lb/>9-BBN(A 0.5-M THF solution, 14.7 mL,
                                    7.34 mmol) is added to the solution which put 44 (0.94 g, 1.83 mmol) in dry THF (50
                                    mL),<lb/>The liquid mixture is stirred at the bottom room temperature of N2 airflow
                                    for 12 hours,<lb/>20% of NaOH solution (4 mL) and 30% of H2O2 solution (4 mL) were
                                    added.<lb/>Next, after recirculate|refluxing [ for 1 hour ] and adding salt water
                                    (100 mL) continuously in the obtained liquid mixture, it extracted using EtOAc (4x30
                                    mL).<lb/>The set extract was dried on anhydrous Na2SO4.<lb/>After removing the
                                    solvent, by refine|purifying the residue with the SiO2 chromatography (It is 10% of
                                    MeOH in CH2Cl2 EtOAc and after that.), the product (0.559 g, yield 54%) was obtained
                                    as colorless oil.
                                </p>
                                <p xml:id="_bb67360928" n="0134">Compound 46:<lb/>PPTS(0.124 g, 0.49 mmol) was added to
                                    the solution which put 45 (0.559 g, 0.98 mmol) in acetone (40 mL) and water (4 mL),
                                    and the solution was recirculate|refluxed under N2 airflow for 16 hours.<lb/>The
                                    solvent was removed under reduced pressure.<lb/>Then, water (40 mL) was added to the
                                    residue, and the liquid mixture was extracted using EtOAc (40 mL, 2x20 mL).
                                    <lb/>
                                    After wash|cleaning the set extract with salt water and drying, it evaporated and
                                    dried.<lb/>The product (0.509 g, yield 98%) which will target the residue when SiO2
                                    column chromatography (It is 8% of MeOH in CH2Cl2.) is performed was obtained as
                                    transparent oil.
                                </p>
                                <p xml:id="_bb67360934" n="0135">Compound 47:<lb/>Et3N(0.168mL, 1.20mmol) is added to
                                    the dry CH2Cl2(10mL) solution of 46 (0.18 g, 0.344 mmol) at 0 degreeC,<lb/>Then, the
                                    mesyl chloride (0.088 mL, 1.13 mmol) was added.<lb/>H2O (3 mL) and salt water (30
                                    mL) were added 10 minutes afterward.<lb/>This liquid mixture was extracted by EtOAc
                                    (30 mL, 2x10 mL), and that extract was dried on anhydrous Na2SO4 to washing|cleaning
                                    and the next with salt water.<lb/>After removing the solvent, the residue was
                                    melt|dissolved in DMSO (5 mL) and NaN3(0.233g, 3.44mmol).<lb/>The suspension was
                                    heated to 50 degreeC under N2 airflow for 12 hours.<lb/>H2O (50 mL) is added to the
                                    cooled suspension,<lb/>After extracting the liquid mixture obtained using EtOAc (30
                                    mL, 2x10 mL), the extract was dried on washing|cleaning and anhydrous Na2SO4 with
                                    salt water.<lb/>The product (yield 88% (0.191 g and 2 processes)) was obtained as
                                    light yellow oil by applying to SiO2 column chromatography (EtOAc / hexane 1:5).
                                </p>
                                <p xml:id="_bb67360944" n="0136">Compound 11:<lb/>Compound 47 (0.191 g, 0.319 mmol) was
                                    melt|dissolved in dry THF (20 mL), and LiAlH4(60.4mg, 1.59mmol) was added
                                    continuously.<lb/>Gray suspension was stirred at room temperature under N2 airflow
                                    for 12 hours.<lb/>The Na2SO4*10H2O powder was added carefully.<lb/>After the gray of
                                    the suspension lose|disappeared, anhydrous Na2SO4 was added, and the
                                    deposit|precipitate was filtered and remove|eliminated.<lb/>After removing the
                                    solvent, column chromatography (Silica gel and MeOH/CH2Cl2/28%NH3*H20 3:3:1)
                                    refine|purified the residue.<lb/>After removing a most solvent from the collected
                                    fractions, 5% of HCl solution (2 mL) was added, and the residue of the shape of the
                                    milk|loop was melt|dissolved.<lb/>The obtained transparent solution was continuously
                                    extracted using Et2O (2x10 mL).<lb/>Next, 20% of NaOH solution was added until the
                                    solution became a strong basicity.<lb/>The basic solution was extracted using
                                    CH2Cl2(20mL, 2*10mL).<lb/>When the set extract was dried on anhydrous Na2SO4 and the
                                    solvent was removed, the target product (0.115 g, yield 69%) was obtained as
                                    colorless oil.<lb/>It is clearer than &lt;1&gt;H NMR that this compound is a mixture
                                    which consists of two stereoisomers of the blend ratio of about 9:1 by C20.
                                    <lb/>
                                    Although these stereoisomers were not isolate|separated, it re-Žû(ed) and used.
                                    <lb/>
                                    The spectrum of the isomer of a direction with much quantity,
                                </p>
                                <p xml:id="_bb67360958" n="0137">Example 6<lb/>Compound 48:
                                    <lb/>
                                    Et3N(48.8(micro|micron|mu)L, 0.35mmol) is added to the dry CH2Cl2(15mL) solution of
                                    23 (0.15 g, 0.233 mmol) at 0 degreeC,<lb/>Then, CH3SO2Cl(21.7(micro|micron|mu)L,
                                    0.28mmol) was added.<lb/>This liquid mixture was stirred for 15 minutes, and H2O (3
                                    mL) was added.<lb/>Next, the saturated NaCl solution (20 mL) was added and the
                                    liquid mixture was extracted by EtOAc (40 mL, 2x20 mL).<lb/>The set extract was
                                    wash|cleaned with salt water and it dried on anhydrous Na2SO4.<lb/>After carrying
                                    out the evaporation removal of the solvent, NaBr(0.12 g, 1.17 mmol) and DMF (10 mL)
                                    were added to the residue.<lb/>This suspension was heated to 80 degreeC under N2
                                    airflow for 2 hours.<lb/>After pressure-reducing and removing DMF, the product
                                    (0.191 g, yield 97%) made into the objective was obtained as light yellow oil by
                                    covering the residue over a chromatography (EtOAc / hexane 1:10) on a silica.
                                </p>
                                <p xml:id="_bb67360968" n="0138">Compound 49:<lb/>Compound 48 (0.191 g, 0.269 mmol) and
                                    23 (0.295 g, 0.459 mmol) are melt|dissolved in DMF(3 mL was distilled on BaO at 6
                                    mmHg, before using it.),<lb/>Then, NaH (inside of a mineral oil 0.054 g, 60 %) was
                                    added.<lb/>The suspension was stirred at room temperature under N2 airflow for 24
                                    hours.<lb/>H2O (100 mL) is added and excess NaH is quenched,<lb/>Next, the extract
                                    with which the liquid mixture was match|combined after extracting using Et2O(40mL,
                                    3*20mL) is wash|cleaned with salt water,<lb/>It dried on anhydrous Na2SO4.<lb/>The
                                    target product (Yield 52% based on 0.177 g and the compound 23) was obtained as pale
                                    yellow oil by applying to a chromatography (EtOAc / hexane 1:6, then 1:2) on SiO2.
                                </p>
                                <p xml:id="_bb67360976" n="0139">Compound 12:<lb/>Compound 49 (0.219 g, 0.173 mmol) was
                                    melt|dissolved in dry THF (10 mL), and LiAlH4(65mg, 1.73mmol) was added
                                    continuously.<lb/>Gray suspension was stirred at room temperature under N2 airflow
                                    for 12 hours.<lb/>The Na2SO4*10H2O powder was added carefully.<lb/>After the gray of
                                    the suspension lose|disappeared, anhydrous Na2SO4 was added, and the
                                    deposit|precipitate was filtered and remove|eliminated.<lb/>After removing the
                                    solvent, column chromatography (Silica gel and MeOH/CH2Cl2/28%NH3*H20 2.5:2.5:1)
                                    refine|purified the residue.<lb/>After carrying out the funnel beta- removal
                                    (rotavapped off) of the most solvent from the collected fractions, 5% of HCl
                                    solution (2 mL) was added, and the residue of the shape of the milk|loop was
                                    melt|dissolved.<lb/>The obtained transparent solution was continuously extracted
                                    using Et2O (2x10 mL).<lb/>Next, 20% of NaOH solution was added until the solution
                                    became a strong basicity.<lb/>The basic solution was extracted using CH2Cl2(20mL,
                                    2*10mL).<lb/>When the set extract was dried on anhydrous Na2SO4 and the solvent was
                                    removed, the product (0.147 g, yield 76%) made into the objective was obtained as a
                                    white glassy material.
                                </p>
                                <p xml:id="_bb67360987" n="0140">Example 7<lb/>Compound 116 a-d:<lb/>A typical
                                    procedure: Preparation of 116b.<lb/>(It described in Li and J. Am. Chem. Soc. 1998,
                                    120, 2961.) which added NaH(0.06 G, 60-% mineral oil solution, 1.49 mmol) and a
                                    propyl bromide (0.136 ml 1.49 mmol) to the DMF solution of the compound 23 (0.096 g,
                                    0.149 mmol).<lb/>Suspension was stirred under N2 for 24 hours.<lb/>H2O (20 ml) was
                                    added and hexane extracted the liquid mixture (it is 3 times about 10 ml).<lb/>It
                                    was made to dry on Na2SO4 and the combined extract was concentrated under vacuum.
                                    <lb/>The desired product was acquired as pale yellow oil by the silica gel
                                    chromatography (hexane solution of 10-%EtOAc) (92 mg, yield 90%).
                                </p>
                                <p xml:id="_bb67360995" n="0141">Compounds 111-113:<lb/>A typical procedure: 112
                                    preparations.<lb/>LiAlH4(0.031 g, 0.81 mmol) was added after melt|dissolving
                                    compound 116b(0.092 g, 0.134 mmol) in THF (10 ml).<lb/>Suspension was stirred under
                                    N2 for 12 hours.<lb/>Na2SO4*10H2O(-1 g) was added carefully.<lb/>After the gray of
                                    suspension lose|disappeared, anhydrous Na2SO4 was added and filtration removed the
                                    deposit.<lb/>When it concentrated and the silica gel chromatography (It is 10:5:1 to
                                    CH2Cl2/MeOH/28%NH3*H2O, 12:6:1, and the next.) was performed, glass was obtained and
                                    this was melt|dissolved in 1 M HCl (2 ml).<lb/>Et2O (it is 2 times at 10 ml)
                                    wash|cleaned the obtained transparent solution.<lb/>The NaOH solution was added to
                                    the water phase 20% until the solution became strong base.<lb/>The basic solution
                                    was extracted using CH2Cl2 (it is 3 times about 10 ml).<lb/>When it was made to dry
                                    on anhydrous Na2SO4 and the combined extract was concentrated under vacuum, the
                                    desired product was acquired as white glass (0.045 g, yield 55%).
                                </p>
                                <p xml:id="_bb67361006" n="0142">Example 8<lb/>Compound 124<lb/>Compound 47(0.256 g,
                                    0.489 mmol) was melt|dissolved in CH2Cl2(10 ml) and it cooled at 0 degreeC,
                                    <lb/>
                                    Then, Na2HPO4(0.69 g, 4.89 mmol), and urea and a hydrogen peroxide compound material
                                    (UHP)(0.069 g, 0.733 mmol) were added.<lb/>The anhydrous trifluoroacetic acid
                                    (TFAA)(0.138 ml, 0.977 mmol) was dripped.<lb/>Suspension was stirred for 12 hours,
                                    and also UHP (23 mg, 0.25 mmol) and TFAA(0.069 ml, 0.49 mmol) were added.<lb/>EtOAc
                                    (it is 3 times at 20 ml) extraction of the liquid mixture obtained by adding H2O (30
                                    ml) in 12 more hours was carried out.<lb/>Wash|cleaned the combined extract with
                                    salt water (50 ml), and it was made to dry on anhydrous Na2SO4, and concentrated
                                    under vacuum.<lb/>When the SiO2 chromatography (EtOAc/hexane, 1:5) was performed,
                                    the desired product was acquired as colorless oil (0.145 g, yield 55%).
                                </p>
                                <p xml:id="_bb67361015" n="0143">Compound 106<lb/>Compound 124(0.145 g, 0.236 mmol) was
                                    melt|dissolved in CH2Cl2(2 ml) and MeOH (1 ml).<lb/>The NaOH solution (0.2 ml) was
                                    added 20%.<lb/>The liquid mixture was stirred for 12 hours, anhydrous Na2SO4 was
                                    added, and the water|moisture content was removed.<lb/>Under vacuum, after
                                    concentration, when the silica gel chromatography (EtOAc/hexane, 1:3)
                                    refine|purified residue, the desired product was acquired as colorless oil (0.124 g,
                                    yield 92%).<lb/>LiAlH4(33 mg, 0.866 mmol) was added after melt|dissolving alcohol
                                    (0.124 g, 0.216 mmol) in anhydrous THF (20 ml).<lb/>Gray suspension was stirred
                                    under N2 for 12 hours.<lb/>Na2SO4*10H2O(-2g) was added carefully.<lb/>After the gray
                                    of suspension lose|disappeared, anhydrous Na2SO4 was added, and the deposit was
                                    filtered and removed.<lb/>After removing a solvent, column chromatography (SiO2,
                                    MeOH/CH2Cl2/28%NH3*H2O, 2.5:2.5:1) refine|purified residue.<lb/>After concentrating
                                    an appropriate fraction, 1M HCl (2 ml) was added and milk|loop-like residue was
                                    melt|dissolved.<lb/>Et2O (it is 2 times about 10 ml) wash|cleaned the obtained
                                    transparent solution.<lb/>The NaOH solution was added to the water phase 20% until
                                    the solution became strong base.<lb/>The basic solution was extracted using CH2Cl2
                                    (it is 2 times about 10 ml 20 ml).<lb/>When the combined extract was dried on
                                    anhydrous Na2SO4 and the solvent was removed, the desired product was acquired as
                                    colorless oil (0.050 g, yield 47%).
                                </p>
                                <p xml:id="_bb67361030" n="0144">Example 9<lb/>Compound 126<lb/>The compound 125 (2.30
                                    g, 3.52 mmol) was melt|dissolved in MeOH (50 ml) and CH2Cl2(100 ml).<lb/>A small
                                    amount of Et3N was added and the solution was cooled at -78 degreeC.<lb/>Ozone was
                                    ventilate|passed in the solution until it remained without a blue color
                                    disappearing.<lb/>After adding Me2S (4 ml), the MeOH (10 ml) solution of NaBH4(0.266
                                    g, 0.703 mmol) was added.<lb/>The obtained solution was heated and it stirred
                                    overnight.<lb/>The solution was concentrated under vacuum and salt water (60 ml) was
                                    added.<lb/>EtOAc (it is 2 times about 30 ml 40 ml) extracted the liquid mixture, the
                                    combined extract was wash|cleaned with salt water, and it was made to dry on
                                    anhydrous Na2SO4.<lb/>When the silica gel chromatography (EtOAc) was performed, the
                                    product was acquired as white solid (1.24 g, yield 76%).
                                </p>
                                <p xml:id="_bb67361040" n="0145">Compound 127<lb/>The compound 126 (1.24 g, 2.67 mmol)
                                    was melt|dissolved in MeOH (30 ml), and NaOH(0.54 g, 13.4 mmol) was added.
                                    <lb/>
                                    Suspension was recirculate|refluxed under N2 for 24 hours.<lb/>H2O was added after
                                    removing MeOH under vacuum (50 ml).<lb/>The deposit was filtered, and when it was
                                    made to dry in vacuum after wash|cleaning by H2O, white solid (1.02 g) was obtained.
                                    <lb/>After melt|dissolving this solid in DMF (40 ml), NEt3(1.12 ml, 8.02 mmol),
                                    DMAP(16.3 mg, 0.13 mmol) and the chlorinated trityl (1.49 g, 5.34 mmol) were added
                                    continuously.<lb/>After stirring suspension under N2 for 12 hours, it heated to 50
                                    degreeC for 24 hours.<lb/>H2O (100 ml) was added to cooled suspension, and EtOAc (it
                                    is 3 times about 50 ml) extracted the liquid mixture.<lb/>Wash|cleaned the combined
                                    extract with salt water (100 ml), and it was made to dry on anhydrous Na2SO4, and
                                    concentrated under vacuum.<lb/>When the silica gel chromatography (EtOAc) was
                                    performed, the product was acquired as pale yellow glass (1.20 g, yield 72%).
                                    <lb/>
                                    Anhydrous THF (80 ml) and NaH(A 60-% mineral oil solution, 0.77 g, 19.3 mmol) were
                                    added to this glass.<lb/>After carrying out half-an-hour recirculation|reflux of
                                    suspension under N2, the allyl bromide (1.67 ml 19.3 mmol) was added.<lb/>After
                                    recirculate|refluxing for 48 hours, NaH and allyl-bromide 10 equivalence were added.
                                    <lb/>The reaction liquid mixture was cooled 48 more hours afterward, and H2O (100
                                    ml) was added gradually.<lb/>Hexane (it is 3 times at 50 ml) extracted the obtained
                                    liquid mixture, the combined extract was wash|cleaned with salt water (100 ml), and
                                    it was made to dry on anhydrous Na2SO4.<lb/>When the silica gel chromatography
                                    (hexane solution of 5-%EtOAc) was performed, the product was acquired as transparent
                                    glass (1.27 g, three steps of all yield 64%).
                                </p>
                                <p xml:id="_bb67361056" n="0146">Compound 128<lb/>9-BBN (0.5 a M THF solution, 17.1 ml)
                                    was added to the THF (40 ml) solution of 127 (1.27 g, 1.71 mmol).<lb/>After stirring
                                    the liquid mixture for 12 hours, NaOH (20-% solution, 10 ml) and H2O2 (30-%
                                    solution, 10 ml) were added.<lb/>After recirculate|refluxing the obtained liquid
                                    mixture for 1 hour, salt water (100 ml) was added and EtOAc (it is 4 times at 30 ml)
                                    extracted.<lb/>It was made to dry by anhydrous Na2SO4 and the set extract was
                                    concentrated in vacuum.<lb/>When the silica gel chromatography (The CH2Cl2 solution
                                    of 5-%MeOH) was performed, the product was acquired as transparent glass (1.26 g,
                                    yield 93%).
                                </p>
                                <p xml:id="_bb67361062" n="0147">Compound 129<lb/>After adding Et3N(0.92 ml, 6.60 mmol)
                                    to the CH2Cl2(50 ml) solution of the compound 128 (1.26 g, 1.58 mmol) at 0 degreeC,
                                    the chlorinated mesyl (0.47 ml 6.05 mmol) was added.<lb/>15 minutes afterward, after
                                    adding H2O (10 ml), salt water (80 ml) was added.<lb/>EtOAc (it is 2 times about 30
                                    ml 60 ml) extracted the liquid mixture, and it dried the combined extract on
                                    anhydrous Na2SO4.<lb/>After removing a solvent under vacuum, residue was
                                    melt|dissolved in DMSO (10 ml) and NaN3(1.192 g, 18.3 mmol) was added.
                                    <lb/>
                                    Suspension was heated to 60 degreeC under N2 overnight.<lb/>H2O (100 ml) was added
                                    and EtOAc (it is 3 times about 40 ml) extracted the liquid mixture.<lb/>Salt water
                                    wash|cleaned the combined extract and it made it dry on anhydrous Na2SO4.<lb/>When
                                    the solvent was removed under vacuum, pale yellow oil was obtained.<lb/>Oil was
                                    melt|dissolved in MeOH (10 ml) and CH2Cl2(20 ml) and TsOH(17.4 mg, 0.092 mmol) were
                                    added.<lb/>Saturated NaHCO3 aqueous solution (20 ml) and salt water (50 ml) were
                                    added 12 hours afterward, and EtOAc (it is 3 times about 40 ml) extracted the liquid
                                    mixture.<lb/>Salt water (50 ml) wash|cleaned the combined extract, and it made it
                                    dry on anhydrous Na2SO4.<lb/>When the silica gel chromatography (EtOAc/hexane, 1:3)
                                    was performed, the desired product was acquired as pale yellow oil (0.934 or 94 %).
                                </p>
                                <p xml:id="_bb67361075" n="0148">Compound 109<lb/>LiAlH4(59 mg, 1.56 mmol) was added
                                    after melt|dissolving compound 129(0.245 g, 0.391 mmol) in THF (30 ml).<lb/>Gray
                                    suspension was stirred under N2 for 12 hours.<lb/>The Na2SO4*10H2O powder (-1 g) was
                                    added carefully.<lb/>After the gray of suspension lose|disappeared, anhydrous Na2SO4
                                    was added and filtration removed the deposit.<lb/>After removing a solvent, the
                                    silica gel chromatography (It is 10:5:1.5 to CH2Cl2/MeOH/28%NH3*H2O, 10:5:1, and the
                                    next.) refine|purified residue.<lb/>The solvent was removed from the appropriate
                                    fraction, 1M HCl (4 ml) was added, and residue was melt|dissolved.<lb/>Et2O (it is 3
                                    times about 10 ml) extracted the obtained transparent solution.<lb/>The NaOH
                                    solution was added 20% until the solution became strong base.<lb/>The basic solution
                                    was extracted using CH2Cl2 (it is 4 times about 10 ml).<lb/>When the set extract was
                                    dried on anhydrous Na2SO4 and the solvent was removed under vacuum, the desired
                                    product was acquired as colorless oil (0.15 g, yield 71%).
                                </p>
                                <p xml:id="_bb67361086" n="0149">Example 10<lb/>Compound 130<lb/>Half-an-hour stirring
                                    of o-NO2C6H4SeCN(0.094 g, 0.21 mmol) and the Bu3P(0.095 ml, 0.38 mmol) was carried
                                    out at 0 degreeC in anhydrous THF (5 ml),<lb/>Then, the THF solution (2 ml) of
                                    compound 129(0.10 g, 0.159 mmol) was added.<lb/>After stirring suspension for 1
                                    hour, H2O2 (30-% aqueous solution, 2 ml) was added.<lb/>After stirring a liquid
                                    mixture for 12 hours, hexane (it is 4 times about 10 ml) extracted.<lb/>The combined
                                    extract was dried on anhydrous Na2SO4.<lb/>When the silica gel chromatography
                                    (10-%EtOAc / hexane) was performed, the desired product was acquired as pale yellow
                                    oil (0.035 g, yield 36%).
                                </p>
                                <p xml:id="_bb67361094" n="0150">Compound 108<lb/>Compound 130(0.105 g, 0.172 mmol) was
                                    melt|dissolved in CH2Cl2(5 ml) and MeOH (5 ml) at -78 degreeC.<lb/>O3 was
                                    ventilate|passed for about 20 minutes in the solution.<lb/>Me2S (1 ml) was added and
                                    the solvent was removed under vacuum.<lb/>Residue was melt|dissolved in THF (15 ml)
                                    and LiAlH4(0.033 g, 0.86 mmol) was added.<lb/>Suspension was stirred for 12 hours.
                                    <lb/>Na2SO4*10H2O(-2 g) was added carefully.<lb/>After the gray of suspension
                                    lose|disappeared, anhydrous Na2SO4 was added and filtration removed the deposit.
                                    <lb/>White glass was obtained, when it concentrated and the silica gel
                                    chromatography (It is 9:6:1.8 to CH2Cl2/MeOH/28%NH3*H2O, 10:5:1.5, and the next.)
                                    was performed.<lb/>1 M HCl (4 ml) was added to this material.<lb/>Et2O (it is 3
                                    times about 10 ml) wash|cleaned the obtained transparent solution.<lb/>The NaOH
                                    solution was added to the water phase 20% until the solution became strong base.
                                    <lb/>The basic solution was extracted using CH2Cl2 (it is 4 times about 10 ml).
                                    <lb/>
                                    When the combined extract was dried on anhydrous Na2SO4 and the solvent was removed,
                                    the desired product was acquired as colorless oil (0.063 g, yield 68%).
                                </p>
                                <p xml:id="_bb67361108" n="0151">Example 11<lb/>Compound 132<lb/>Compound 115(0.118 g,
                                    0.183 mmol) is melt|dissolved in anhydrous CH2Cl2(10 ml),<lb/>The SO3* pyridine
                                    composite_body|complex (0.035 g, 0.22 mmol) was added.<lb/>Suspension was stirred
                                    for 12 hours.<lb/>The white powder was obtained when the solvent was removed under
                                    vacuum.<lb/>CH2Cl2 (it is 4 times about 10 ml) extracted the liquid mixture obtained
                                    by adding 1 M HCl (10 ml) to a white powder.<lb/>The combined extract was dried on
                                    anhydrous Na2SO4.<lb/>When the silica gel chromatography (The CH2Cl2 solution of
                                    10-%MeOH) was performed, the desired product was acquired as pale yellow oil (0.11
                                    g, 84 %).<lb/>The azide was reduce|restored by treating the tri azide (0.11 g, 0.15
                                    mmol) with THF (10 ml) of Ph3P(0.20 g, 0.77 mmol), and an H2O (1 ml) solution.
                                    <lb/>
                                    Three days of liquid mixture were stirred.<lb/>When the solvent was removed under
                                    vacuum and the silica gel chromatography (CH2Cl2/MeOH/28%NH3*H2O, 12:6:1, next
                                    10:5:1.5) refine|purified residue, the desired product was acquired as glass (0.077
                                    g, yield 78%).<lb/>When the Et2O(1 M, 0.5 ml) solution of HCl was added to glass,
                                    the corresponding HCl salt was obtained.
                                </p>
                                <p xml:id="_bb67361121" n="0152">Compound 133<lb/>The mesylate (0.19 g, 0.264 mmol)
                                    originating in 23 was stirred at 80 degreeC with an excessive quantity of octyl
                                    amines (2 ml) for 12 hours.<lb/>After removing an octyl amine under vacuum, when the
                                    chromatography (2-%Et3N is added to a silica gel, EtOAc/hexane, and 1:4.) of residue
                                    was performed, the desired product was acquired as pale yellow oil (0.19 g, yield
                                    95%).<lb/>The tri azide (0.18 g, 0.239 mmol) was melt|dissolved in THF (10 ml) and
                                    EtOH (10 ml).<lb/>The Lindlar catalyst (44 mg) was added and suspension was shaken
                                    under H2 (50 psi) for 12 hours.<lb/>After removing a solvent under vacuum, the
                                    silica gel chromatography (It is 10:5:1.5 to CH2Cl2/MeOH/28%NH3*H2O, 10:5:1, and the
                                    next.) refine|purified residue.<lb/>Et2O (it is 2 times about 10 ml) extracted the
                                    transparent solution obtained by adding 1 M HCl (2 ml) to this product.<lb/>The NaOH
                                    solution was added 20% until the solution became strong base.<lb/>The basic solution
                                    was extracted using CH2Cl2 (it is 2 times about 10 ml 20 ml).<lb/>When the combined
                                    extract was dried on Na2SO4 and the solvent was removed under vacuum, the desired
                                    product was acquired as transparent oil (0.114 g, yield 68%).
                                </p>
                                <p xml:id="_bb67361131" n="0153">Compound 134<lb/>The compound 133 (0.08 g, 0.12 mmol)
                                    is melt|dissolved in CHCl3 (5 ml) and MeOH (5 ml),<lb/>The amino imino sulfonic acid
                                    (0.045 g, 0.36 mmol) was added, and suspension was stirred for 12 hours.<lb/>The
                                    solvent was removed under vacuum and residue was melt|dissolved in 1 M HCl (6 ml)
                                    and H2O (10 ml).<lb/>Et2O (it is 3 times about 5 ml) wash|cleaned the solution, and
                                    the NaOH solution was dripped 20% until the solution became strong base.<lb/>CH2Cl2
                                    (it is 4 times about 5 ml) extracted the basic liquid mixture.<lb/>When it was made
                                    to dry on anhydrous Na2SO4 and the combined extract was concentrated in vacuum, the
                                    desired product was acquired as white glass (0.087 g, yield 91%).<lb/>Compound 135
                                    <lb/>NaN3(0.0167 g, 0.256 mmol) was added after melt|dissolving the mesylate
                                    originating in 23(0.092 g, 0.128 mmol) in DMSO (2 ml).<lb/>Suspension was heated at
                                    70 degreeC for 12 hours.<lb/>H2O (20 ml) was added to cooled suspension, and
                                    EtOAc/hexane (1:1) (it is 3 times about 10 ml 20 ml) extracted the liquid mixture.
                                    <lb/>Salt water (30 ml) wash|cleans the combined extract,<lb/>It is made to dry on
                                    anhydrous Na2SO4.<lb/>When concentrated under vacuum, the product was acquired as
                                    pale yellow oil (0.081 g, yield 95%).<lb/>The tetra-azide (0.081 g, 0.12 mmol) was
                                    melt|dissolved in THF (5 ml) and EtOH (10 ml).<lb/>The Lindlar catalyst (30 mg) was
                                    added and suspension was shaken under H2 (50 psi) for 12 hours.<lb/>After removing a
                                    solvent under vacuum, the silica gel chromatography (It is 2:2:1 to
                                    CH2Cl2/MeOH/28%NH3*H2O, 5:3:1, and the next.) refine|purified residue.<lb/>Et2O (it
                                    is 2 times about 10 ml) wash|cleaned the solution obtained by adding 1 M HCl (2 ml)
                                    to this product.<lb/>The NaOH solution was added to the water phase 20% until the
                                    solution became strong base.<lb/>The basic solution was extracted using CH2Cl2 (it
                                    is 2 times about 5 ml 10 ml).<lb/>When it was made to dry on anhydrous Na2SO4 and
                                    the combined extract was concentrated under vacuum, the desired product was acquired
                                    as colorless oil (0.044 g, yield 64%).
                                </p>
                                <p xml:id="_bb67361152" n="0154">Example 12<lb/>A compound 203a-b, 207a-c, 208a-c,
                                    209a-c and 210 a-b<lb/>When BOC-glycine was made to react with DCC, DMAP, and the
                                    call acid derivative 201 (scheme 11), triester 202a was obtained with the favorable
                                    yield.<lb/>Reaction of the resemblance|analogue which incorporates BOC-(beta)
                                    alanine was successful similarly, and obtained 202b.<lb/>When the dioxan solution of
                                    HCl deprotected and refine|purified 202a and 202b, (The SiO2 chromatography by a
                                    CH2Cl2MeOH/NH4OH eluting agent) and triester 203a and 203b were obtained with the
                                    favorable yield.
                                </p>
                                <p xml:id="_bb67361157" n="0155">The triamide of glycine and (beta) alanine
                                    (respectively 207a and 207b) was formed using the same reaction conditions (scheme
                                    12).<lb/>The triamide by (alpha) branch amino acid can be formed similarly.<lb/>For
                                    example, on the described conditions, the triamide which has a bis|screw BOC-lysine
                                    side chain was formed (compound 207c).<lb/>When the THF solution and methanol of
                                    LiOH hydrolyzed C24 ester of 207 a-c, alcohol 208 a-c was obtained.<lb/>When
                                    deprotected using the dioxan solution of HCl (208 a-c), triamide 209 a-c was
                                    obtained with the favorable yield.<lb/>The alcohol 208a and 208b was mesylated, and
                                    it was made to react with the benzyl methylamine in addition.<lb/>The triamides 210a
                                    and 210b (scheme 12) were obtained by the deprotection by the dioxan solution of HCl
                                    of the obtained compound.<lb/>The antibacterial property of these compounds is
                                    summarized in Table 14.
                                </p>
                                <p xml:id="_bb67361165" n="0156">Example 13<lb/>Compound 302<lb/>The compound 308
                                    (5(beta)- cholanoic acid, 3,7,12- trion methyl ester) was prepared from cholic-acid
                                    methyl, and the dichromic-acid pyridinium was produced|generated substantially
                                    quantitatively from cholic-acid methyl.<lb/>The compound 308 is also Pearson
                                    (Pearson) et al. (J. Chem. Soc. Perkins Trans. 1, 1985, 267);<lb/>Mitra (J. Org.
                                    Chem. 1968, 33, 175);<lb/>And it can prepare as described in Takeda (Takeda) et al.
                                    (J. Biochem. (Tokyo)1959, 46, 1313).<lb/>The compound 308 was processed for 12 hours
                                    in ethanol which recirculate|refluxes by a hydroxylamine hydrochloride and sodium
                                    acetate (Hsieh et al., Bioorg. Med. Chem. 1995, 3, 823), and 309 was obtained by
                                    yield 97%.
                                </p>
                                <p xml:id="_bb67361172" n="0157">250 Glyme|Grimm (100 ml) was added to the 3 head flask
                                    of ml, and 309 (1.00 g, 2.16 mmol) and borohydride sodium (2.11 g, 55.7 mmol) were
                                    added to this.<lb/>TiCl4(4.0 ml, 36.4 mmol) was slowly added to the mixture at 0
                                    degreeC under nitrogen.<lb/>It recirculate|refluxed for further 12 hours, after
                                    stirring the obtained green liquid mixture at room temperature for 24 hours.<lb/>The
                                    flask was cooled in the ice bath and ammonium hydroxide (100 ml) was added.<lb/>The
                                    obtained liquid mixture was stirred at room temperature for 6 hours.
                                    <lb/>
                                    Concentrated HCl (60 ml) was added slowly and the acidic liquid mixture was stirred
                                    for 8 hours.<lb/>Suspension obtained by adding the solid KOH was made into
                                    alkalinity.<lb/>Suspension was filtered and MeOH wash|cleaned solid.<lb/>The
                                    filtrate and washing|cleaning liquid which were set were set and it concentrated
                                    under vacuum.<lb/>The obtained solid was suspended in 6-%KOH aqueous solution (100
                                    ml), and CH2Cl2 (it is 4 times about 75 ml) extracted.<lb/>1.14 g White solid was
                                    obtained, when the combined extract was dried on Na2SO4 and the solvent was removed
                                    in vacuum.<lb/>In the liquid mixture, when the chromatography was performed on the
                                    silica gel (CH2Cl2/MeOH/NH4OH, 12:6:1), 302 (0.282 g, yield 33%), 3 (0.066 g, yield
                                    8%), and 4 (0.118 g, yield 14%) were obtained.
                                </p>
                                <p xml:id="_bb67361184" n="0158">Example 14<lb/>It can prepare, as the compound of the
                                    formula I is also shown to a following example.
                                </p>
                                <p xml:id="_bb67361186" n="0159">Example 15<lb/>The test of the compound by
                                    Gram-negative bacteria<lb/>MIC and a MBC measurement<lb/>Whole:<lb/>Microorganisms:
                                    The reference|standard strain|stump|stock was purchased from the bacto roll disk of
                                    American Type Culture Collection (Rockville, Maryland state) or a Difco laboratories
                                    (Detroit, Michigan state).<lb/>The following specific ATCC strain|stump|stocks were
                                    used.<lb/>10798 colon_bacillus|E._coli, 25922 colon_bacillus|E._coli, the 13883
                                    Klebsiella pneumonia bacillus (Klebsiella pneumoniae),<lb/>27853 Psudomonas
                                    aeruginosa (Pseudomonas aeruginosa), 14028 Salmonella typhimurium (Salmonella
                                    typhimurium),<lb/>29212 Enterococcus faecalis (Enterococcus faecalis),<lb/>25923
                                    Staphylococcus aureus (Staphylococcus aureus), 19615 Streptococcus pyogenes
                                    (Streptococcus pyogenes), and a 90028 Candida albicans (Candida albicans).<lb/>The
                                    bacteria strain was maintained on the Mueller-Hinton agar plate, and the Candida
                                    albicans (Candida albicans) was maintained on the Sabourand dextrose agar plate.
                                </p>
                                <p xml:id="_bb67361197" n="0160">Trypsin degradation soybean juice (TBS) melt|dissolves
                                    27.5 g of the dextrose -not-containing trypsin degradation soybean juice (DIFCO
                                    Laboratories) in 1 liter deionized water,<lb/>It sterilized and created at 121
                                    degreeC for 15 minutes.<lb/>Solid agar (TSA) plate melt|dissolves 6.4 g of trypsin
                                    degradation soybean juice, and 12-g agar (The thing of the refined grade, Fischer
                                    Scientific) in 800 mL deionized water,<lb/>Sterilization treatment was carried out
                                    at 121 degreeC for 20 minute(s), and it created.<lb/>Next, the aliquot (20 mL) of
                                    the homogeneous solution was inject|poured into sterilized plastics Petri dishes
                                    (100*15mm, Fisher Scientific).<lb/>The solution of the compound melt|dissolved in
                                    the sterilized water which a suitable quantity deionized, and ultrafiltered and
                                    created each HCl salt.
                                </p>
                                <p xml:id="_bb67361203" n="0161">The typical method which measures MIC and a MBC value
                                    <lb/>From the culture incubated at 37 degreeC in TSB for 24 hours, suspension
                                    containing colon_bacillus|E._coli (ATCC 10798) of -10 &lt;6&gt;CFU (colony forming
                                    unit) / mL was prepared.<lb/>It added to the test tube containing the call acid
                                    derivative which changed the density|concentration so that aliquot 1mL of this
                                    suspension might be increased step by step with 1 mL TSB and/or an erythromycin, or
                                    a novobiocin.<lb/>In this sensitivity experiment, the erythromycin or the novobiocin
                                    was added 15 minutes afterward from the call acid derivative.<lb/>Rest
                                    culture|cultivation was performed for this sample at 37 degreeC for 24 hours.
                                    <lb/>
                                    The turbidity of the sample was determined by measuring the light absorbency in 760
                                    nm (HP 8453 UV-Visible Chemstation, Hewett Packard).<lb/>Furthermore, the aliquot
                                    obtained from each sample without turbidity to the extent that it can measure is on
                                    TSA plate, and it carried out the secondary culture.<lb/>(The aliquot was diluted so
                                    that it might be set to 300 or less CFU.).<lb/>After incubating overnight, the
                                    colony increased by the secondary-culture thing was counted, and the number of
                                    CFU/mL contained in a sample was computed.<lb/>The computed value was compared with
                                    the number of CFU/mL of the first inoculum.<lb/>After incubating a MIC value for 24
                                    hours, it determined whether it as or reduced with the constant number of CFU/mL as
                                    a density|concentration of the investigated compound.<lb/>The MBC value was
                                    determined as lowest density|concentration that can survive 0.1% or less of the
                                    investigated compound of the original bacterial suspension.
                                </p>
                                <p xml:id="_bb67361215" n="0162">Example 16<lb/>Authentication of film|membrane
                                    non-permeability of a call acid derivative<lb/>The present inventors clarified that
                                    a call acid derivative increased the permeability|transmittance of
                                    outside-film|membrane of Gram-negative bacteria using the method described in J. M.
                                    Shupp, S. E. Travis, L. B. Price, R. F. Shand, P. Keim, Rapid Bacterial
                                    Permeabilization Reagent Useful For Enzyme Assays, Biotechniques, 1995, vol. 19,
                                    18-20.<lb/>Value (The permeability|transmittance of outside-film|membrane which
                                    accept|permits that luciferin enters into a cell is shown.) of the half of largest
                                    light emission is [ 2 ] 33 micrograms/mL about 7 micrograms/mL and 10.<lb/>These
                                    values respond|correspond to MIC measured about 2 and 10.
                                </p>
                                <p xml:id="_bb67361220" n="0163">Result<lb/>It is known that PMB has film|membrane
                                    permeability and a bactericidal characteristic.<lb/>PMB has a hydrophobic acyl
                                    group, and D amino acid and the macrocyclic heptapeptide containing four
                                    diaminobutyric acid (DAB) residues.<lb/>One of the DAB side chains is concerned in
                                    formation of a huge ring, and other three side chains are still free amines.
                                    <lb/>
                                    Thus, PMB has a row|line|column of the amine orient|assigned to a surface with the
                                    one side of a hydrophobic scaffold structure, i.e., a plane.<lb/>It is suggested to
                                    specific arrangement|positioning required in order to couple|bond the main roles of
                                    a huge ring with the lipid A part of LPS that it is orient|assigning an amine group.
                                    <lb/>The relative spatial directionality of such primary amine groups is the same as
                                    the case of PMB also in a call acid derivative.
                                </p>
                                <p xml:id="_bb67361227" n="0164">By the stereochemical difference in a steroid
                                    structure, the active difference in a call acid derivative (compare 2, 8, Table 1,
                                    2, and 6 and 7) arises.<lb/>A MIC value becomes low rather than the compound in
                                    which the compound which has the guanidine group couple|bonded with steroid contains
                                    an amine group (Compare 1, 2, 4, and 5 and compare Table 1- 8.).<lb/>The length of
                                    the chain|strand between an amine group or a guanidine group, and a steroid
                                    structure also affects it active (compare 1-3, Table 1, 2, and 6 and 7).<lb/>The
                                    chain|strand of ester between an amine group and a steroid structure has a MIC value
                                    higher than the corresponding compound containing the chain|strand of ether (compare
                                    1, 2, 6, 7, and Table 1 and 2).
                                </p>
                                <p xml:id="_bb67361231" n="0165">The group couple|bonded with C-20 of frame|skeleton or
                                    C-24 also affects the activity of a call acid derivative.<lb/>When long carbon chain
                                    has couple|bonded with steroid through an ether bond by C-24, compared with the
                                    compound which has couple|bonded the hydroxyl group with C-24, MIC of the compound
                                    will become small (Compare 2, 9, 10, Table 1, 2, and 6 and 7.).<lb/>When the short
                                    chain|strand of carbon or oxygen has couple|bonded with C-20, the MIC value of a
                                    call acid derivative will become small (compare 10, 11, and Table 1 and 2).<lb/>The
                                    call acid derivative covalently bonded makes the activity of the compound increase
                                    (compare 10, 12, and Table 1 and 2).
                                </p>
                                <p xml:id="_bb67361235" n="0166">The capability to permeabilize|transparentize
                                    outside-film|membrane<lb/>It investigated about the antibiotic activity of the
                                    compounds 11, 106, 108-114 (FIG. 1).<lb/>They tested also about the capability to
                                    make into permeability|transmittance outside-film|membrane of Gram-negative bacteria
                                    which causes the sensitization with respect to hydrophobic antibiotics which cannot
                                    pass outside-film|membrane.<lb/>Permeabilization|transparentization of
                                    outside-film|membrane was measured using the erythromycin and the novobiocin.
                                    <lb/>
                                    These antibiotics are inactive to Gram-negative bacteria because of the obstacle
                                    formed of outside-film|membrane of Gram-negative bacteria with respect to
                                    Gram-positive bacteria although it was active.
                                </p>
                                <p xml:id="_bb67361240" n="0167">Almost all experiment was conducted using E.. coli K-12
                                    strain ATCC 10798;<lb/>However, in order to authenticate that the activity of a call
                                    acid derivative is not species specific, the activity of the selected compound was
                                    measured also about Psudomonas aeruginosa (Pseudomonas aeruginosa)(ATCC 27853).
                                    <lb/>
                                    MIC of the erythromycin with respect to colon_bacillus|E._coli (ATCC 10798) and the
                                    novobiocin was measured by 70 and &gt;500 microg/ml.<lb/>The threshold value
                                    measured value regarding permeabilization|transparentization was a
                                    density|concentration of the call acid derivative required in order to reduce an
                                    erythromycin or MIC in any one of a novobiocin to 1 microg/ml.
                                </p>
                                <p xml:id="_bb67361244" n="0168">The result of MIC, MBC, and a
                                    permeabilization|transparentization (based on erythromycin) measurement is shown in
                                    FIG. 2 (In FIG. 2, the compound A is polymyxin B nonapeptide.).<lb/>As shown in FIG.
                                    2, MIC and the MBC value of the compound fell dramatically as the length of the side
                                    chain expand|extended from C-17 increased.<lb/>The clear role of a hydrophobic
                                    steroidal side chain is accelerating|stimulating adhesion on a film|membrane, and
                                    the self propulsion transport after the first time association|meeting with
                                    outside-film|membrane of Gram-negative bacteria (it shows in FIG. 3 like).
                                    <lb/>
                                    Permeabilization|transparentization of outside-film|membrane occurs as a result of
                                    association|meeting with the lipid A on the lobule of the outer side of a
                                    film|membrane.<lb/>Only by permeabilization|transparentization of
                                    outside-film|membrane, a cell death was not caused, but this has suggested that
                                    outside-film|membrane must be passed, in order for a compound to kill bacteria.
                                    <lb/>
                                    Since a compound has lethal activity, the passage ability of outside-film|membrane
                                    and the destructive ability of the cytoplasmic membrane by it are required.
                                </p>
                                <p xml:id="_bb67361250" n="0169">The compound which does not have a hydrophobic side
                                    chain has a weak germicidal action so that it may be recognized.<lb/>Although these
                                    compounds can make outside-film|membrane permeability|transmittance (That is, it
                                    associates with the lipid A on the lobule of the outer side of a film|membrane.),
                                    the postulate that outside-film|membrane cannot be passed is built up.
                                </p>
                                <p xml:id="_bb67361252" n="0170">The fraction inhibitory concentration (FIC) value of
                                    the compound was calculated using an erythromycin and a novobiocin as a secondary
                                    compound.<lb/>The compound showed less than 0.5 FIC value by having made 114 into
                                    the exception regarding the erythromycin, and there also existed a value
                                    close|similar to 0.05 in inside (Table 9).
                                </p>
                                <p xml:id="_bb67361254" n="0171">The detail of the test using a novobiocin is similarly
                                    shown in Table 9.<lb/>The fact that the result depended on an erythromycin and a
                                    novobiocin was equivalent has shown that the activity of a call acid derivative is
                                    not dependent to antibiotics.<lb/>The similar tendency was recognized also about
                                    colon_bacillus|E._coli (ATCC 10798) and Psudomonas aeruginosa (P. aeruginosa)(ATCC
                                    27853),<lb/>However,<lb/>As it estimated|forecast, Psudomonas aeruginosa (P.
                                    aeruginosa) was resistance from colon_bacillus|E._coli.<lb/>These results have
                                    suggested that the activity of the investigated compound is not dependent as a
                                    species.
                                </p>
                                <p xml:id="_bb67361260" n="0172">The compound which has the hydrophobic alkylamino alkyl
                                    side chain was prepared (the compounds 133 and 134, FIG. 4).<lb/>As it recognized
                                    about the other compound, when the guanidine group was incorporated (134), the
                                    activity of the call acid derivative increased compared with the compound containing
                                    a primary amine.<lb/>As a control, 135 (FIG. 4) which does not have a hydrophobic
                                    side chain was prepared.<lb/>MIC of the control|contrast (135) was comparatively
                                    high as expected similarly to MBC (FIG. 5).<lb/>by contrast, MIC of 133 and 134 was
                                    very low -- those activity was actually equal to PMB.<lb/>Especially 133, 134, and
                                    MBC of PMB were very similar with MIC.<lb/>Namely, a threshold value
                                    density|concentration<lb/>WHEREIN:<lb/>These compounds killed all the bacteria in a
                                    solution.
                                </p>
                                <p xml:id="_bb67361269" n="0173">As further means to authenticate the film|membrane
                                    destructive ability of the call acid derivatives 133 and 134, the cytolysis assay
                                    based on luciferin/luciferase was used.<lb/>(The passage of description to
                                    Willardson (Willardson), Appl. Environ. Microbiol. 1998, 64, 1006, Schaap (Schupp),
                                    and Biotechniques 1995, 19, 18).<lb/>This assay<lb/>WHEREIN:
                                    <lb/>
                                    Colon_bacillus|E._coli containing the plasmid which codes an induction type
                                    luciferase was incubated with the inducer (toluene),<lb/>Then, it processed with the
                                    melt|dissolution buffer solution containing one either and Triton X-100 of PMB or a
                                    call acid derivative.<lb/>Next, luciferin and ATP were added.<lb/>Light emission
                                    occurred by cytolysis.<lb/>The density|concentration of the film|membrane
                                    destructive substance (PMB and call acid derivative) was changed, and obtained light
                                    emission was measured.<lb/>Light emission was not recognized when a film|membrane
                                    destructive substance did not exist.
                                </p>
                                <p xml:id="_bb67361279" n="0174">A density|concentration required for MIC and
                                    half-largest light emission of 133, 134, and PMB is shown in FIG. 6.<lb/>The
                                    activity of the compounds 133 and 134 is equal to the activity of PMB in the light
                                    emission assay similarly to the case of a MIC value.
                                </p>
                                <p xml:id="_bb67361281" n="0175">The effect|action of sulfate group<lb/>In order that
                                    presence of the sulfate group of C-24 in a call acid derivative might observe
                                    whether the activity of a compound is made to increase, 132 (it shows in FIG. 7) was
                                    investigated.<lb/>MIC of 132 by colon_bacillus|E._coli (ATCC 10798) was 60
                                    microg/ml.<lb/>The density|concentration required in order to reduce MIC of an
                                    erythromycin to 1 microg/ml was 4.0 microg/ml about the same strain|stump|stock.
                                    <lb/>The antibiotic activity and permeabilization|transparentization activity of 132
                                    were lower than the activity of the alcohol 110 (it shows in FIG. 1) which is a
                                    parent compound.
                                </p>
                                <p xml:id="_bb67361286" n="0176">Further experiment<lb/>Further experiment was conducted
                                    using compound 1, 2, 5, 106, 10, 112, 133 and 134.<lb/>About the typical
                                    strain|stump|stock of a Gram negative and a gram-positive living organism|raw_food,
                                    MIC and MBC data of these compounds are shown in Table 10.<lb/>For the comparison
                                    objective, MIC of PMB by various living organism|raw_foods is also measured, and it
                                    shows in Table 10.
                                </p>
                                <p xml:id="_bb67361290" n="0177">Compound 1, 2, 5, 106, 10, 112, 133 and 134 other than
                                    PMB share other steroid antibiotics and a certain characteristics.<lb/>For example,
                                    squalamine contains a steroid nucleus and a polyamine side chain.<lb/>(Moore, Proc.
                                    Natl. Acad. Sci. 1993, 90, 1354-1358).<lb/>It is advocated that squalamine is
                                    incorporated in a lipid bilayer and destroys a bacteria film|membrane.
                                    <lb/>
                                    Squalamine<lb/>WHEREIN:<lb/>Polar polyamine functionality exists in the distal
                                    terminal of a molecule|numerator, and leaves a hydrophobic core.<lb/>In 1, 2, 5,
                                    106, 10, 112, 133 and 134, an amine exists in the one side of steroid and gives an
                                    amphiphilic compound externally.<lb/>1, 2, 5, 106, 10, 112, 133 and a series of
                                    another compounds relevant to 134 contain in C -24 position the call acid derivative
                                    which has an amine (for example, 140 of FIG. 7).<lb/>By contrast [ 1, 2, 5, 106, 10,
                                    112, 133 and 134 ], these compounds have the very weak antimicrobial activity with
                                    respect to Gram-positive bacteria, and not showing activity to Gram-negative
                                    bacteria is shown.
                                </p>
                                <p xml:id="_bb67361300" n="0178">Call acid derivative 1, 2, 5, 106, 10, 112, 133 and 134
                                    show an active width|variety, and there exist some which show MIC below the
                                    microgram/ml in inside.<lb/>MIC and a MBC value are very similar with the most
                                    active high compound especially with respect to many living organism|raw_foods.
                                    <lb/>
                                    Probably some of compounds show the lethal activity by destruction of a cytoplasmic
                                    membrane.<lb/>Others only have a sub- lethal activity by
                                    permeabilization|transparentization of outside-film|membrane.
                                </p>
                                <p xml:id="_bb67361304" n="0179">Although the compound (for example, 106 and 10) which
                                    lose|deletes a hydrophobic chain|strand has a high MIC value, it is an effective
                                    permeation|transmission agent of outside-film|membrane of Gram-negative bacteria.
                                    <lb/>In order that these compounds may lose|delete a hydrophobic chain|strand, they
                                    have the activity which is sub-lethal and is not lethal with respect to these
                                    bacteria.<lb/>The compound (for example, 133 and 134) which has a hydrophobic
                                    chain|strand has lethal activity.
                                </p>
                                <p xml:id="_bb67361307" n="0180">It has suggested that they can act as a film|membrane
                                    destructive substance in call acid derivative 1, 2, 5, 106, 10, 112, 133 and the
                                    hemoclasis of 134, and that those antimicrobial activity is probably accompanied by
                                    a destruction of membrane.<lb/>Regarding Gram-negative bacteria, an inactive target
                                    is estimate|forecasted as it is a cytoplasmic membrane.<lb/>A compound like 106 and
                                    10 cannot pass outside-film|membrane effectively, and does not show lethal activity.
                                    <lb/>The hydrophobic chain|strand in 133 and 134 may accelerate|stimulate the self
                                    propulsion transport which passes along outside-film|membrane, and may destroy a
                                    cytoplasmic membrane by it.
                                </p>
                                <p xml:id="_bb67361311" n="0181">As for the result shown in Table 10, presence of a
                                    hydrophobic chain|strand has shown that takes active lethal and it is not so
                                    important with respect to Gram-positive bacteria.<lb/>Even if it is not satisfying
                                    the requirements which pass outside-film|membrane, the compound which lose|deletes
                                    the hydrophobic chain|strand expand|extended from C-17 can kill Gram-positive
                                    bacteria effectively.
                                </p>
                                <p xml:id="_bb67361313" n="0182">The length of various coupling|bondings was
                                    investigated and the amine or the optimal space|interval of the guanidine group was
                                    determined from steroid.<lb/>It became clear that three carbon bonds produced a more
                                    effective compound than the compound of two carbon bonds.<lb/>(For example, MIC of 1
                                    is compared with MIC of two.).<lb/>The increase in the antibiotic activity acquired
                                    when a guanidine group is substituted by an amine has suggested the central role of
                                    an amine / guanidine phosphoric acid interaction.
                                </p>
                                <p xml:id="_bb67361317" n="0183">The characteristic of the group couple|bonded with the
                                    steroid structure by C-17 exerted influence on the activity of the compound with
                                    respect to Gram-negative bacteria large.<lb/>For example, the difference of MIC
                                    regarding 106, 10, and 112 and a MBC value was remarkable.<lb/>Also in MIC and the
                                    MCB value of 2 and 5, this tendency was recognized compared with the value of 133
                                    and 134.<lb/>(This comparison<lb/>WHEREIN:<lb/>The benzyl group of 2 and 5 is
                                    estimate|forecasted as hydrophobicity is lower than the octyl chain|strand
                                    recognized in 133 and 134.).<lb/>The influence of the group couple|bonded with
                                    steroid by C-17 is not so remarkable in Gram-positive bacteria, and 5 and 134 have a
                                    similar MIC value with respect to Staphylococcus aureus (Staphylococcus aureus), for
                                    example.
                                </p>
                                <p xml:id="_bb67361324" n="0184">In order to measure
                                    permeabilization|transparentization, compound 1, 2, 5, 106, 10, 112, 133 and the FIC
                                    value of 134 by the erythromycin, the novobiocin, and a rifampicin were determined.
                                    <lb/>The density|concentration of the call acid derivative required in order to
                                    block|prevent bacteria growth of Gram-negative bacteria was determined using 0.5 of
                                    these antibiotics, 1.0, or the density|concentration of 3.0 microg/ml.<lb/>A
                                    density|concentration required for bacteria growth blockage|prevention and a FIC
                                    value are shown to Tables 11-13.<lb/>The MIC value of a compound is not directly
                                    correlated with an interesting thing at the permeabilization|transparentization
                                    ability of outside-film|membrane.<lb/>For example, although the compounds 106 and 10
                                    have a comparatively high MIC value, they are forceful
                                    permeabilization|transparentization agents.<lb/>Almost all of the compound showed
                                    less than 0.5 FIC value, and there also existed less than 0.03 compound in inside.
                                    <lb/>The call acid derivatives (namely, 5, 133, and 134) which produce a
                                    comparatively high FIC value are forceful antibiotics in itself.
                                </p>
                                <p xml:id="_bb67361331" n="0185">Ester and the amide|amido side chain<lb/>The compound
                                    which has the further compound, for example, amide|amido, and an ester side chain
                                    was investigated.<lb/>The compounds 203b, 6, and 210a (scheme 12) showed forceful
                                    synergism with an erythromycin and a novobiocin (Table 14).<lb/>In a series of
                                    triester (203a, 203b, 6 and 7), (beta) alanine origin compound is highly active than
                                    the compound originating in glycine.<lb/>The substitution of C24 hardly exerted
                                    influence on the activity of these compounds (203b and 7, and comparison).
                                </p>
                                <p xml:id="_bb67361336" n="0186">Probably triamide 209 a-c (scheme 12) was for the
                                    structural constraint given by the amide bond, or its activity was lower than ester.
                                    <lb/>When substituted by C24 regarding the triamide, significant influence was
                                    exerted on the activity of the compound.<lb/>(It compares with 209a and 210a, and is
                                    Table 14.).<lb/>This series<lb/>WHEREIN:<lb/>The glycine derivative was highly
                                    active than corresponding (beta) alanine derivative.
                                </p>
                                <p xml:id="_bb67361342" n="0187">The relative lack of the synergism shown with the
                                    lysine derivative|guide_body may be caused to the length of a side chain.<lb/>As a
                                    control, the derivative|guide_body of 209c which lose|deletes the compound 211 (FIG.
                                    8) and the (alpha)- amino group was prepared.<lb/>This compound had activity weaker
                                    than 209c as a permeabilization|transparentization agent.<lb/>It was authenticated
                                    that the compound 206 is not also effective as a permeabilization|transparentization
                                    agent.<lb/>From these results, it is suggested that the optimal length of the
                                    coupling|bonding between steroid and an amine functional group is from zero to six
                                    atoms.
                                </p>
                                <p xml:id="_bb67361347" n="0188">
                                    <figure xml:id="_bb67361349">
                                        <graphic url="/1"/>
                                    </figure>
                                    The measurement of the value of MIC and MBC of 1-12 using colon_bacillus|E._coli
                                    (ATCC 10798)<lb/>A &lt;a&gt; value is un-measuring.
                                </p>
                                <p xml:id="_bb67361351" n="0189">
                                    <figure xml:id="_bb67361353">
                                        <graphic url="/1"/>
                                    </figure>
                                    The measurement of the density|concentration of 1-12 required for lowering MIC of a
                                    70 to 1 microgram/mL erythromycin using colon_bacillus|E._coli (ATCC 10798)<lb/>A
                                    &lt;a&gt; value is un-measuring.
                                </p>
                                <p xml:id="_bb67361355" n="0190">
                                    <figure xml:id="_bb67361357">
                                        <graphic url="/1"/>
                                    </figure>
                                    The measurement of the density|concentration of 1, 2, 4, and 5 required for lowering
                                    MIC of a &gt;500 microgram/mL to 1 microgram/mL novobiocin using
                                    colon_bacillus|E._coli (ATCC 10798)<lb/>A &lt;a&gt; value is un-measuring.
                                </p>
                                <p xml:id="_bb67361359" n="0191">
                                    <figure xml:id="_bb67361361">
                                        <graphic url="/1"/>
                                    </figure>
                                    Colon_bacillus|E._coli (ATCC 25922) is used and it is the measurement of the value
                                    of MIC and MBC of 1, 2, 4, and 5.
                                </p>
                                <p xml:id="_bb67361362" n="0192">
                                    <figure xml:id="_bb67361364">
                                        <graphic url="/1"/>
                                    </figure>
                                    The measurement of the density|concentration of 1, 2, 4, and 5 required for lowering
                                    MIC of a 60 to 1 microgram/mL erythromycin using colon_bacillus|E._coli (ATCC 25922)
                                </p>
                                <p xml:id="_bb67361365" n="0193">
                                    <figure xml:id="_bb67361367">
                                        <graphic url="/1"/>
                                    </figure>
                                    P. aureginosa(ATCC 27853) is used and it is the measurement of the value of MIC and
                                    MBC of 1-5, 8-12.<lb/>A &lt;a&gt; value is un-measuring.
                                </p>
                                <p xml:id="_bb67361369" n="0194">
                                    <figure xml:id="_bb67361371">
                                        <graphic url="/1"/>
                                    </figure>
                                    The measurement of the density|concentration of 1-5, 8-12 required for lowering MIC
                                    of a 240 to 5 micrograms/mL erythromycin using P. aureginosa(ATCC 27853)<lb/>A &lt;a&gt;
                                    value is un-measuring.
                                </p>
                                <p xml:id="_bb67361373" n="0195">
                                    <figure xml:id="_bb67361375">
                                        <graphic url="/1"/>
                                    </figure>
                                    The measurement of the density|concentration of 1, 2, 4, and 5 required for lowering
                                    MIC of a &gt;500 microgram/mL to 1 microgram/mL novobiocin using P. aureginosa(ATCC
                                    27853)
                                </p>
                                <p xml:id="_bb67361376" n="0196">
                                    <figure xml:id="_bb67361378">
                                        <graphic url="/1"/>
                                    </figure>
                                    Table 9. MIC of colon_bacillus|E._coli (ATCC 10798), MBC,
                                    permeabilization|transparentization, and FIC data.<lb/>(a) A density|concentration
                                    required in order to reduce MIC of an erythromycin to 70 to 1 microgram/mL.<lb/>(b)
                                    MBC of a 1 microgram/mL erythromycin.<lb/>(c) The FIC value of an erythromycin.
                                    <lb/>
                                    (d) A density|concentration required in order to reduce MIC of a novobiocin to &gt;500
                                    to 1 microgram/mL.<lb/>(e) The FIC value of a novobiocin.
                                </p>
                                <p xml:id="_bb67361384" n="0197">
                                    <figure xml:id="_bb67361386">
                                        <graphic url="/1"/>
                                    </figure>
                                </p>
                                <p xml:id="_bb67361387" n="0198">
                                    <figure xml:id="_bb67361389">
                                        <graphic url="/1"/>
                                    </figure>
                                </p>
                                <p xml:id="_bb67361390" n="0199">
                                    <figure xml:id="_bb67361392">
                                        <graphic url="/1"/>
                                    </figure>
                                </p>
                                <p xml:id="_bb67361393" n="0200">
                                    <figure xml:id="_bb67361395">
                                        <graphic url="/1"/>
                                    </figure>
                                </p>
                                <p xml:id="_bb67361396" n="0201">
                                    <figure xml:id="_bb67361398">
                                        <graphic url="/1"/>
                                    </figure>
                                    a: The density|concentration of a call acid derivative required in order to decrease
                                    MIC of an erythromycin to 1 microgram/ML.<lb/>b: The density|concentration of a call
                                    acid derivative required in order to decrease MIC of a novobiocin to 1 microgram/ML.
                                </p>
                                <p xml:id="_bb67361400" n="0202">Another aspect<lb/>All the characteristics disclosed to
                                    this specification are combinable with arbitrary combinations.<lb/>You may
                                    substitute each characteristics disclosed by this specification with the same, the
                                    equivalent, or another characteristics that fulfill|perform the similar objective.
                                    <lb/>Thus, especially each characteristics disclosed unless it wrote in a separate
                                    paragraph and stated are mere examples in a series of general equivalent
                                    characteristics or the similar characteristics.
                                </p>
                                <p xml:id="_bb67361404" n="0203">The expert can confirm the essential characteristics of
                                    this invention easily from said description, and it is possible to perform a
                                    deformation|transformation and modification of the versatility of this invention so
                                    that this invention may adapt a various using method and conditions, without
                                    deviating from the mind and range.<lb/>For example, the salt, ester, ether, and
                                    amide|amido of the novel steroid compound disclosed to this specification are
                                    contained in the scope of the present invention.<lb/>Thus, another aspect is also
                                    contained in this claim.
                                </p>
                                <head xml:id="_bb67361407">BRIEF DESCRIPTION OF THE DRAWINGS</head>
                                <p xml:id="_bb67361408"><lb/>FIG. 1 :It is a figure which shows the compound of this
                                    invention.<lb/>FIG. 2 :It is a graph which shows MIC and the MBC value of each
                                    compound with the density|concentration of the compound of this invention required
                                    in order to reduce MIC of an erythromycin to 1 microg/ml.<lb/>FIG. 3 :It is
                                    schematic drawing which shows the mechanism of action proposed about a call acid
                                    derivative.<lb/>FIG. 4 :It is a figure which shows the compound of this invention.
                                    <lb/>FIG. 5 :It is a graph which shows MIC and the MBC value of a compound of this
                                    invention.<lb/>FIG. 6 :It is a graph which shows the MIC value of the compound of
                                    this invention.<lb/>FIG. 7 :It is a figure which shows the compound 132.<lb/>FIG. 8
                                    :It is a figure which shows the compound 211.
                                </p>
                            </div>
                        </body>
                    </text>
                </group>
            </text>
        </TEI>
    </teiCorpus>
</teiCorpus>